1
|
Speel EJ, Radonic T, Dafni U, Thunnissen E, Rüschoff J, Kowalski J, Kerr K, Bubendorf L, Valero IS, Joseph L, Navarro A, Monkhorst K, Madsen L, Losa JH, Biernat W, Dellaporta T, Kammler R, Peters S, Stahel R, Finn S. 191P ROS1 fusions in resected stage I-III adenocarcinoma (ADC): A Lungscape ETOP study. J Thorac Oncol 2023. [DOI: 10.1016/s1556-0864(23)00444-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/04/2023]
|
2
|
Delio M, Bryke C, Mendez L, Joseph L, Jassim S. JAK2 Mutations Are Rare and Diverse in Myelodysplastic Syndromes: Case Series and Review of the Literature. Hematol Rep 2023; 15:73-87. [PMID: 36810551 PMCID: PMC9944460 DOI: 10.3390/hematolrep15010008] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2022] [Revised: 11/15/2022] [Accepted: 01/04/2023] [Indexed: 01/20/2023] Open
Abstract
OBJECTIVES To investigate and characterize JAK2 mutations in myelodysplastic syndrome (MDS), we present three cases with diverse JAK2 mutations and review the literature. METHODS The institutional SoftPath software was used to find MDS cases between January 2020 and April 2022. The cases with a diagnosis of a myelodysplastic/myeloproliferative overlap syndrome including MDS/MPN with ring sideroblasts and thrombocytosis were excluded. The cases with molecular data by next generation sequencing looking for gene aberrations commonly seen in myeloid neoplasms were reviewed for the detection of JAK2 mutations including variants. A literature review on the identification, characterization, and significance of JAK2 mutations in MDS was performed. RESULTS Among 107 cases of the MDS reviewed, a JAK2 mutation was present in three cases, representing 2.8% of the overall cases. A JAK2 V617F mutation was found in one case representing slightly less than 1% of all the MDS cases. In addition, we found JAK2 R564L and JAK2 I670V point mutation variants to be associated with a myelodysplastic phenotype. CONCLUSIONS JAK2 mutations in MDS are rare and represent less than 3% of cases. It appears that JAK2 variant mutations in MDS are diverse and further studies are needed to understand their role in the phenotype and prognosis of the disease.
Collapse
Affiliation(s)
- Melissa Delio
- Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
| | - Christine Bryke
- Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
| | - Lourdes Mendez
- Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
| | - Loren Joseph
- Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
| | - Sarmad Jassim
- Department of Pathology, William Beaumont Hospital, Royal Oak, MI 48073, USA
- Correspondence:
| |
Collapse
|
3
|
Taniere P, Nicholson A, Gosney J, Joseph L, Shaw E, Lanctot A, Bains R, Ryan J. PATHways UK survey: Pathology perceptions on current biomarker testing and pathways for breast cancer in England. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)01595-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
4
|
Lascarrou JB, Dumas F, Bougouin W, Legriel S, Aissaoui N, Deye N, Beganton F, Lamhaut L, Jost D, Vieillard-Baron A, Nichol G, Marijon E, Jouven X, Cariou A, Agostinucci J, Aissaoui-Balanant N, Algalarrondo V, Alla F, Alonso C, Amara W, Annane D, Antoine C, Aubry P, Azoulay E, Beganton F, Billon C, Bougouin W, Boutet J, Bruel C, Bruneval P, Cariou A, Carli P, Casalino E, Cerf C, Chaib A, Cholley B, Cohen Y, Combes A, Coulaud J, Da Silva D, Das V, Demoule A, Denjoy I, Deye N, Diehl J, Dinanian S, Domanski L, Dreyfuss D, Dubois-Rande J, Dumas F, Duranteau J, Empana J, Extramiana F, Fagon J, Fartoukh M, Fieux F, Gandjbakhch E, Geri G, Guidet B, Halimi F, Henry P, Jabre P, Joseph L, Jost D, Jouven X, Karam N, Lacotte J, Lahlou-Laforet K, Lamhaut L, Lanceleur A, Langeron O, Lavergne T, Lecarpentier E, Leenhardt A, Lellouche N, Lemiale V, Lemoine F, Linval F, Loeb T, Ludes B, Luyt C, Mansencal N, Mansouri N, Marijon E, Maury E, Maxime V, Megarbane B, Mekontso-Dessap A, Mentec H, Mira J, Monnet X, Narayanan K, Ngoyi N, Perier M, Piot O, Plaisance P, Plaud B, Plu I, Raphalen J, Raux M, Revaux F, Ricard J, Richard C, Riou B, Roussin F, Santoli F, Schortgen F, Sharshar T, Sideris G, Spaulding C, Teboul J, Timsit J, Tourtier J, Tuppin P, Ursat C, Varenne O, Vieillard-Baron A, Voicu S, Wahbi K, Waldmann V. Differential Effect of Targeted Temperature Management Between 32 °C and 36 °C Following Cardiac Arrest According to Initial Severity of Illness: Insights From Two International Data Sets. Chest 2022; 163:1120-1129. [PMID: 36445800 DOI: 10.1016/j.chest.2022.10.023] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2022] [Revised: 10/10/2022] [Accepted: 10/23/2022] [Indexed: 11/27/2022] Open
Abstract
BACKGROUND Recent guidelines have emphasized actively avoiding fever to improve outcomes in patients who are comatose following resuscitation from cardiac arrest (ie, out-of-hospital cardiac arrest). However, whether targeted temperature management between 32 °C and 36 °C (TTM32-36) can improve neurologic outcome in some patients remains debated. RESEARCH QUESTION Is there an association between the use of TTM32-36 and outcome according to severity assessed at ICU admission using a previously derived risk score? STUDY DESIGN AND METHODS Data prospectively collected in the Sudden Death Expertise Center (SDEC) registry (France) between May 2011 and December 2017 and in the Resuscitation Outcomes Consortium Continuous Chest Compressions (ROC-CCC) trial (United States and Canada) between June 2011 and May 2015 were used for this study. Severity at ICU admission was assessed through a modified version of the Cardiac Arrest Hospital Prognosis (mCAHP) score, divided into tertiles of severity. The study explored associations between TTM32-36 and favorable neurologic status at hospital discharge by using multiple logistic regression as well as in tertiles of severity for each data set. RESULTS A total of 2,723 patients were analyzed in the SDEC data set and 4,202 patients in the ROC-CCC data set. A favorable neurologic status at hospital discharge occurred in 728 (27%) patients in the French data set and in 1,239 (29%) patients in the North American data set. Among the French data set, TTM32-36 was independently associated with better neurologic outcome in the tertile of patients with low (adjusted OR, 1.63; 95% CI, 1.15-2.30; P = .006) and high (adjusted OR, 1.94; 95% CI, 1.06-3.54; P = .030) severity according to mCAHP at ICU admission. Similar results were observed in the North American data set (adjusted ORs of 1.36 [95% CI, 1.05-1.75; P = .020] and 2.42 [95% CI, 1.38-4.24; P = .002], respectively). No association was observed between TTM32-36 and outcome in the moderate groups of the two data sets. INTERPRETATION TTM32-36 was significantly associated with a better outcome in patients with low and high severity at ICU admission assessed according to the mCAHP score. Further studies are needed to evaluate individualized temperature control following out-of-hospital cardiac arrest.
Collapse
Affiliation(s)
- Jean Baptiste Lascarrou
- Université Paris Cité, INSERM, PARCC, Paris, France; Médecine Intensive Réanimation, University Hospital Center, Nantes, France; AfterROSC Network Group, Paris, France.
| | - Florence Dumas
- Université Paris Cité, INSERM, PARCC, Paris, France; Emergency Department, Cochin University Hospital, APHP, Paris, France
| | - Wulfran Bougouin
- Université Paris Cité, INSERM, PARCC, Paris, France; AfterROSC Network Group, Paris, France; Medical-Surgical Intensive Care Unit, Hopital Privé Jacques Cartier, Massy, France
| | - Stephane Legriel
- Université Paris Cité, INSERM, PARCC, Paris, France; AfterROSC Network Group, Paris, France; Medical Surgical Intensive Care Unit, Mignot Hospital, Le Chesnay, France
| | - Nadia Aissaoui
- Université Paris Cité, INSERM, PARCC, Paris, France; AfterROSC Network Group, Paris, France; Medical Intensive Care Unit, Cochin Hospital (APHP) and University of Paris, Paris, France
| | - Nicolas Deye
- AfterROSC Network Group, Paris, France; Medical Intensive Care Unit, Lariboisière University Hospital, INSERM U942, Paris, France
| | | | - Lionel Lamhaut
- AfterROSC Network Group, Paris, France; SAMU de Paris-DAR Necker University Hospital-Assistance, Paris, France
| | - Daniel Jost
- Brigade des Sapeurs-Pompiers de Paris, Paris, France
| | - Antoine Vieillard-Baron
- Medical Intensive Care Unit, Ambroise Paré University Hospital, APHP, Boulogne-Billancourt, France
| | - Graham Nichol
- University of Washington-Harborview Center for Prehospital Emergency Care, University of Washington, Seattle, WA
| | - Eloi Marijon
- Université Paris Cité, INSERM, PARCC, Paris, France
| | | | - Alain Cariou
- Université Paris Cité, INSERM, PARCC, Paris, France; AfterROSC Network Group, Paris, France; Medical Intensive Care Unit, Cochin Hospital (APHP) and University of Paris, Paris, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Cassidy M, Hayes R, Nevin R, Griffin A, Herbst J, Mealy B, Walsh K, Donnelly R, Harrison H, Jariol A, Joseph L, Carroll KM. 301 BENEFITS OF ENVIRONMENTAL MUSIC THERAPY IN AN ACUTE HOSPITAL. Age Ageing 2022. [DOI: 10.1093/ageing/afac218.264] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Environmental Music Therapy (EMT) uses live music played by a music therapist to enhance the surrounding environment and is increasingly used in clinical settings. Studies show that EMT may reduce anxiety, enhance wellbeing, promote better communication between patients and staff, and reduce patient perception of waiting times in hospital. We aimed to explore the benefit of EMT for older adults in a geriatric outpatient setting and on rehabilitation wards.
Methods
Harp music was played by a music therapist in the vicinity of ambulatory clinics and on rehabilitation wards for 4 hours per week (over a 2-day period) for 20 weeks. Music exposure on any given day was to an estimated 50 outpatients, as well as 50 people passing the vicinity or to about 30 patients on the rehabilitation ward. Music was selected and played in a dynamic process, responding to verbal and non-verbal reactions of patients, family, and staff. Voluntary responses were recorded and collated.
Results
There were 36 recorded responses and all reflected positively on EMT. Patients cited that the music created a welcoming space and stimulated interaction and conversation. Several patients waiting for their clinic appointment noted that it distracted from fearful expectation and was a source of comfort. Some commented that they felt more relaxed and that it reduced stress. On rehabilitation wards, patients found familiar music to be calming with nurses citing that it stimulated social interaction between patients, family and staff. Responses to EMT gave insights that resulted in patient referrals for music therapy.
Conclusion
Environmental music played by a music therapist was found to modify patient hospital experiences. In particular, it appeared to reduce self-perceived stress and stimulate positive social interaction and conversation. This supports the use of EMT to advance the integration of the arts for wellbeing in an acute hospital.
Collapse
Affiliation(s)
- M Cassidy
- St. James's Hospital Creative Life Centre, Mercer's Institute for Successful Ageing, , Dublin, Ireland
| | - R Hayes
- St. James's Hospital Creative Life Centre, Mercer's Institute for Successful Ageing, , Dublin, Ireland
| | - R Nevin
- St. James's Hospital Creative Life Centre, Mercer's Institute for Successful Ageing, , Dublin, Ireland
| | - A Griffin
- St. James's Hospital Occupational Therapy Department, , Dublin, Ireland
| | - J Herbst
- St. James's Hospital Medical Social Work Department, , Dublin, Ireland
| | - B Mealy
- St. James's Hospital Physiotherapy Department, , Dublin, Ireland
| | - K Walsh
- St. James's Hospital Speech and Language Therapy Department, , Dublin, Ireland
| | - R Donnelly
- St. James’s Hospital Medicine for the Elderly Department, , Dublin, Ireland
| | | | | | - L Joseph
- St. James’s Hospital Medicine for the Elderly Department, , Dublin, Ireland
| | - KM Carroll
- St. James's Hospital Creative Life Centre, Mercer's Institute for Successful Ageing, , Dublin, Ireland
| |
Collapse
|
6
|
Zubiena L, Lewin O, Ogunfiditimi G, Coleman R, Phezulu J, Blackburn T, Joseph L. Development and testing of the Health Information Website Evaluation Tool (HIWET) – An inter-rater reliability analysis study. Physiotherapy 2022. [DOI: 10.1016/j.physio.2021.12.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
7
|
Corbasson A, Meunier B, Lecoeur E, Jannot A, Khimoud D, Namaoui W, Joseph L, Arlet J. Tolérance du vaccin anti-COVID19 chez les patients drépanocytaires adultes. Rev Med Interne 2021. [PMCID: PMC8610706 DOI: 10.1016/j.revmed.2021.10.282] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
Introduction Les patients drépanocytaires adultes sont considérés depuis le début de l’épidémie comme plus fragiles face à la COVID-19. L’analyse de la littérature et des travaux Français montrent que les patients de génotype SC et les plus de 40 ans sont les plus à risque de développer des formes sévères. De plus, des crises vaso-occlusives (CVO) peuvent être provoquées par l’infection, ce qui conduit à des hospitalisations plus fréquentes dans cette population. La vaccination prioritaire a donc été recommandée. Cependant, la tolérance du vaccin n’a pas été étudiée dans cette population, notamment le risque de crise induite par l’inflammation ou la fièvre post-vaccinale. Nous avons souhaité étudier les complications liées au vaccins anti-COVID19 dans une cohorte consécutive de patients drépanocytaires adultes. Patients et méthodes Étude observationnelle rétrospective réalisée sur une cohorte de patients d’un centre de référence Français. Tous les patients de notre cohorte, vaccinés jusqu’au 31 juillet 2021, ont été rappelés systématiquement dans les 2 mois suivant leur injection pour connaître les effets secondaires des vaccins. En plus des effets secondaires attendus, était notifié s’ils avaient eu des CVO à domicile ou des hospitalisations dans les 21 jours suivant le vaccin. La prévalence de CVO hospitalisées a été comparée à celle survenue dans les 3 semaines chez tous les patients drépanocytaires non vaccinés, venus dans la même période en consultation ou hospitalisation de jour (HDJ) dans notre centre. Résultats Sur une cohorte active d’environ 300 patients, seuls 100 patients drépanocytaires (68 % homozygotes, 22 % de génotype SC ; 55 % de femmes) étaient vaccinés au 31/07/2021. 95 % ont reçu un schéma vaccinal complet. 93 patients ont reçu le vaccin Pfizer, 3 le Moderna, 4 l’Astra Zeneca. L’âge médian des sujets vaccinés était de 30 ans (extrêmes 18-67). L’incidence des hospitalisations dans les 3 semaines était de 12 % après la première dose : 9 CVO simples, une CVO avec syndrome thoracique aigu, une thrombose veineuse profonde dans le bras injecté, une CVO avec séquestration splénique et rupture de rate entraînant un décès. Parmi ces 12 patients, quatre avaient été vaccinés dans les 30 jours suivant une CVO hospitalisée (incluant le patient décédé, vacciné à la fin d’une hospitalisation pour CVO). Dans la même période, l’incidence des hospitalisations sur notre cohorte de patients vus en consultation ou HDJ était de 9 % à 3 semaines (27/285) (P = 0,58, comparaison non significative par rapport aux vaccinés). Des CVO gérées à domicile ont été rapportées par 4 patients ayant reçu leur première dose. Les autres complications les plus fréquentes survenant dans les 48 heures suivant la première injection vaccinale étaient les suivantes : douleur musculaire au point d’injection (31 %), asthénie (23 %), courbatures (13 %), céphalées (13 %), fièvre (12 %), [MOU1] [A2] frissons (3 %), nausées (2 %), douleurs oculaires (1 %), orgelet (1 %), règles très douloureuses (1 %), diarrhées (1 %), malaise (1 %), vertiges rotatoires (1 %). Parmi les patients avec fièvre, seuls 2/12 ont été hospitalisés pour CVO. Enfin, seuls deux des 78 patients ayant eu la deuxième injection (2,5 %) ont été hospitalisés dans les 3 semaines (2 CVO). [MOU1]Peut être pas pour l’abstract mais il faudrait regarder si la majortité de ces 12 patients avec fièvre ne sont pas ceux qui ont été hospitalisés. si c’est la cas on pourra rajouter une phrase en ce sens [A2]3 de ces patients ont fait une CVO et seulement 2 ont été hospitalisés. Conclusion La tolérance du vaccin anti-COVID19 est très acceptable chez le patient drépanocytaire adulte, avec des effets secondaires minimes, proches de ceux de la population générale. Nos résultats rassurent sur le risque potentiel de CVO nécessitant une hospitalisation induite par l’injection vaccinale, même si la prudence imposerait de se placer à distance d’une crise pour la réalisation du vaccin. Ces résultats devraient diminuer l’appréhension d’une population à risque de la COVID-19 mais réticente à la vaccination, comme le montre le taux insuffisant de patients vaccinés dans notre cohorte, pourtant régulièrement incités à se faire vacciner depuis mars 2021.
Collapse
|
8
|
Dougherty U, Mustafi R, Zhu H, Zhu X, Deb D, Meredith SC, Ayaloglu-Butun F, Fletcher M, Sanchez A, Pekow J, Deng Z, Amini N, Konda VJ, Rao VL, Sakuraba A, Kwesi A, Kupfer SS, Fichera A, Joseph L, Hart J, He F, He TC, West-Szymanski D, Li YC, Bissonnette M. Upregulation of polycistronic microRNA-143 and microRNA-145 in colonocytes suppresses colitis and inflammation-associated colon cancer. Epigenetics 2021; 16:1317-1334. [PMID: 33356812 PMCID: PMC8813074 DOI: 10.1080/15592294.2020.1863117] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2020] [Revised: 11/08/2020] [Accepted: 12/07/2020] [Indexed: 12/25/2022] Open
Abstract
Because ADAM17 promotes colonic tumorigenesis, we investigated potential miRNAs regulating ADAM17; and examined effects of diet and tumorigenesis on these miRNAs. We also examined pre-miRNA processing and tumour suppressor roles of several of these miRNAs in experimental colon cancer. Using TargetScan, miR-145, miR-148a, and miR-152 were predicted to regulate ADAM17. miR-143 was also investigated as miR-143 and miR-145 are co-transcribed and associated with decreased tumour growth. HCT116 colon cancer cells (CCC) were co-transfected with predicted ADAM17-regulating miRNAs and luciferase reporters controlled by ADAM17-3'UTR. Separately, pre-miR-143 processing by colonic cells was measured. miRNAs were quantified by RT-PCR. Tumours were induced with AOM/DSS in WT and transgenic mice (Tg) expressing pre-miR-143/miR-145 under villin promoter. HCT116 transfection with miR-145, -148a or -152, but not scrambled miRNA inhibited ADAM17 expression and luciferase activity. The latter was suppressed by mutations in ADAM17-3'UTR. Lysates from colonocytes, but not CCC, processed pre-miR-143 and mixing experiments suggested CCC lacked a competency factor. Colonic miR-143, miR-145, miR-148a, and miR-152 were downregulated in tumours and more moderately by feeding mice a Western diet. Tg mice were resistant to DSS colitis and had significantly lower cancer incidence and tumour multiplicity. Tg expression blocked up-regulation of putative targets of miR-143 and miR-145, including ADAM17, K-Ras, XPO5, and SET. miR-145, miR-148a, and miR-152 directly suppress colonocyte ADAM17 and are down-regulated in colon cancer. This is the first direct demonstration of tumour suppressor roles for miR-143 and miR-145 in an in vivo model of colonic tumorigenesis.
Collapse
Affiliation(s)
| | - Reba Mustafi
- Department of Medicine, University of Chicago, Chicago IL, USA
| | - Hongyan Zhu
- Department of Medicine, University of Chicago, Chicago IL, USA
| | - Xiaorong Zhu
- Department of Medicine, University of Chicago, Chicago IL, USA
| | - Dilip Deb
- Department of Medicine, University of Chicago, Chicago IL, USA
| | | | | | | | - Arantxa Sanchez
- Department of Medicine, University of Chicago, Chicago IL, USA
| | - Joel Pekow
- Department of Medicine, University of Chicago, Chicago IL, USA
| | - Zifeng Deng
- Department of Medicine, University of Chicago, Chicago IL, USA
| | - Nader Amini
- Department of Medicine, University of Chicago, Chicago IL, USA
| | - Vani J Konda
- Department of Medicine, Baylor University, Dallas, TX, USA
| | - Vijaya L. Rao
- Department of Medicine, University of Chicago, Chicago IL, USA
| | | | - Akushika Kwesi
- Department of Medicine, University of Chicago, Chicago IL, USA
| | - Sonia S Kupfer
- Department of Medicine, University of Chicago, Chicago IL, USA
| | | | - Loren Joseph
- Departments of Pathology, Beth Israel, Harvard Medical School, Boston, MA, USA
| | - John Hart
- Departments of Pathology, University of Chicago, Chicago IL, USA
| | - Fang He
- Departments of Orthopedics, The University of Chicago, Chicago, IL, USA
| | - Tong-Chuan He
- Departments of Orthopedics, The University of Chicago, Chicago, IL, USA
| | | | - Yan Chun Li
- Department of Medicine, University of Chicago, Chicago IL, USA
| | | |
Collapse
|
9
|
Navarro I, Joseph L, Liu Z, Berlin A, Helou J, Raman S, Weersink R, Rink A, Lao B, Menard C, Chung P. Physician and Patient Reported Morbidity After MR-Guided Salvage Brachytherapy for Prostate Cancer. Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.916] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
10
|
Omar S, Ismail F, Joseph L, Ngcamu D, Okozi N, van der Meulen M, Gwala T, Bhyat Z, Sicwetsha A, de Abreu C, Danisa L, Makubalo L, Ismail N. Bedaquiline resistance and genetic resistance associated variants: South African National Bedaquiline Surveillance program 2014–2019. Int J Infect Dis 2020. [DOI: 10.1016/j.ijid.2020.09.075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
11
|
Nichols M, Stevenson L, Koski L, Basler C, Wise M, Whitlock L, Francois Watkins L, Friedman CR, Chen J, Tagg K, Joseph L, Caidi H, Patel K, Tolar B, Hise K, Classon A, Ceric O, Reimschuessel R, Williams IT. Detecting national human enteric disease outbreaks linked to animal contact in the United States of America. REV SCI TECH OIE 2020; 39:471-480. [PMID: 33046928 DOI: 10.20506/rst.39.2.3098] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Enteric pathogens, such as non-typhoidal Salmonella, Campylobacter and Escherichia coli, can reside in the intestinal tract of many animals, including livestock, companion animals, small mammals and reptiles. Often, these animals can appear healthy; nonetheless, humans can become infected after direct or indirect contact, resulting in a substantial illness burden. An estimated 14% of the 3.2 million illnesses that occur in the United States of America (USA) each year from such enteric pathogens are attributable to animal contact. Surveillance for enteric pathogens in the USA includes the compilation and interpretation of both laboratory and epidemiologic data. However, the authors feel that a collaborative, multisectoral and transdisciplinary - or One Health - approach is needed for data collection and analysis, at every level. In addition, they suggest that the future of enteric illness surveillance lies in the development of improved technologies for pathogen detection and characterisation, such as genomic sequencing and metagenomics. In particular, using whole-genome sequencing to compare genetic sequences of enteric pathogens from humans, food, animals and the environment, can help to predict antimicrobial resistance among these pathogens, determine their genetic relatedness and identify outbreaks linked to a common source. In this paper, the authors describe three recent, multi-state human enteric illness outbreaks linked to animal contact in the USA and discuss how integrated disease surveillance was essential to outbreak detection and response. Additional datasharing between public health and animal health laboratories and epidemiologists at the local, national, regional and international level may help to improve surveillance for emerging animal and human health threats and lead to new opportunities for prevention.
Collapse
|
12
|
Sireci AN, Patel JL, Joseph L, Hiemenz MC, Rosca OC, Caughron SK, Thibault-Sennett SA, Burke TL, Aisner DL. Molecular Pathology Economics 101: An Overview of Molecular Diagnostics Coding, Coverage, and Reimbursement: A Report of the Association for Molecular Pathology. J Mol Diagn 2020; 22:975-993. [PMID: 32504675 PMCID: PMC7267794 DOI: 10.1016/j.jmoldx.2020.05.008] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2019] [Revised: 04/27/2020] [Accepted: 05/18/2020] [Indexed: 11/26/2022] Open
Abstract
Widespread indications for use of molecular diagnostics in various aspects of clinical medicine have driven proliferation of testing. The rapid adoption and continuous technological evolution of molecular diagnostics have often strained the development and maintenance of a functional underlying framework of coding, coverage, and reimbursement policies, thereby presenting challenges to various stakeholders, including molecular professionals, payers, and patients. A multidisciplinary working group convened by the Association for Molecular Pathology Economic Affairs Committee was tasked to describe the complex landscape of molecular pathology economics and highlight opportunities for member engagement. In this article, on the basis of review and synthesis of government regulations and procedures, published payer policy documents, peer-reviewed literature, and expert consensus, the Working Group navigates the ecosystem of molecular pathology economics in terms of stakeholders, coding systems and processes, coverage policy determination, and pricing mechanisms. The composition and interrelatedness of various working groups and committees are emphasized to highlight the functional underpinnings of the system. Molecular professionals must be conversant in the language and complex inner workings of molecular pathology economics to lead successful, viable laboratories and advocate effectively for policy development on their behalf. This overview is provided to be a resource to molecular professionals as they navigate the reimbursement landscape.
Collapse
Affiliation(s)
- Anthony N Sireci
- EAC101 Working Group, a Working Group of the Association for Molecular Pathology Economic Affairs Committee, Rockville, Maryland; Loxo Oncology, a wholly owned subsidiary of Eli Lilly, Stamford, Connecticut
| | - Jay L Patel
- EAC101 Working Group, a Working Group of the Association for Molecular Pathology Economic Affairs Committee, Rockville, Maryland; Department of Pathology, University of Utah and ARUP Laboratories, Salt Lake City, Utah
| | - Loren Joseph
- EAC101 Working Group, a Working Group of the Association for Molecular Pathology Economic Affairs Committee, Rockville, Maryland; Division of Clinical Pathology, Beth Israel Deaconess Medical Center, Boston, Massachusetts
| | - Matthew C Hiemenz
- EAC101 Working Group, a Working Group of the Association for Molecular Pathology Economic Affairs Committee, Rockville, Maryland; Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, California; Department of Pathology, Keck School of Medicine of USC, Los Angeles, California
| | - Oana C Rosca
- EAC101 Working Group, a Working Group of the Association for Molecular Pathology Economic Affairs Committee, Rockville, Maryland; Department of Pathology and Laboratory Medicine, Northwell Health System, Staten Island University Hospital, Staten Island, New York
| | - Samuel K Caughron
- EAC101 Working Group, a Working Group of the Association for Molecular Pathology Economic Affairs Committee, Rockville, Maryland; The MAWD Pathology Group, Lenexa, Kansas
| | | | - Tara L Burke
- Association for Molecular Pathology, Rockville, Maryland
| | - Dara L Aisner
- EAC101 Working Group, a Working Group of the Association for Molecular Pathology Economic Affairs Committee, Rockville, Maryland; Department of Pathology, University of Colorado School of Medicine, Aurora, Colorado.
| |
Collapse
|
13
|
Shamriz O, Simon AJ, Lev A, Megged O, Ledder O, Picard E, Joseph L, Molho-Pessach V, Tal Y, Millman P, Slae M, Somech R, Toker O, Berger M. Exogenous interleukin-2 can rescue in-vitro T cell activation and proliferation in patients with a novel capping protein regulator and myosin 1 linker 2 mutation. Clin Exp Immunol 2020; 200:215-227. [PMID: 32201938 DOI: 10.1111/cei.13432] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2020] [Revised: 03/04/2020] [Accepted: 03/16/2020] [Indexed: 12/27/2022] Open
Abstract
Capping protein regulator and myosin 1 linker 2 (CARMIL2) deficiency is characterized by impaired T cell activation, which is attributed to defective CD28-mediated co-signaling. Herein, we aimed to analyze the effect of exogenous interleukin (IL)-2 on in-vitro T cell activation and proliferation in a family with CARMIL2 deficiency. This study included four children (one male and three females; aged 2·5-10 years at presentation). The patients presented with inflammatory bowel disease and recurrent viral infections. Genetic analysis revealed a novel homozygous 25-base pairs deletion in CARMIL2. Immunoblotting demonstrated the absence of CARMIL2 protein in all four patients and confirmed the diagnosis of CARMIL2 deficiency. T cells were activated in-vitro with the addition of IL-2 in different concentrations. CD25 and interferon (IFN)-γ levels were measured after 48 h and 5 days of activation. CD25 surface expression on activated CD8+ and CD4+ T cells was significantly diminished in all patients compared to healthy controls. Additionally, CD8+ T cells from all patients demonstrated significantly reduced IFN-γ production. When cells derived from CARMIL2-deficient patients were treated with IL-2, CD25 and IFN-γ production increased in a dose-dependent manner. T cell proliferation, as measured by Cell Trace Violet, was impaired in one patient and it was also rescued with IL-2. In conclusion, we found that IL-2 rescued T cell activation and proliferation in CARMIL2-deficient patients. Thus, IL-2 should be further studied as a potential therapeutic modality for these patients.
Collapse
Affiliation(s)
- O Shamriz
- The Lautenberg Center for Immunology and Cancer Research, Institute of Medical Research Israel-Canada, Hebrew University-Hadassah Medical School, Jerusalem, Israel.,Allergy and Clinical Immunology Unit, Department of Medicine, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| | - A J Simon
- Sheba Cancer Research Center and Institute of Hematology, Sheba Medical Center, Tel HaShomer, Ramat-Gan, Israel
| | - A Lev
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.,Pediatric Department A and Immunology Service, Jeffrey Modell Foundation Center, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Affiliated with Tel Aviv University, Tel Aviv, Israel
| | - O Megged
- Pediatric Infectious diseases Unit, Shaare Zedek Medical Center, Jerusalem, Israel
| | - O Ledder
- Juliet Keidan Institute of Pediatric Gastroenterology and Nutrition, Shaare Zedek Medical Center, Jerusalem, Israel
| | - E Picard
- Pediatric pulmonology Unit, Shaare Zedek Medical Center, Jerusalem, Israel
| | - L Joseph
- Pediatric pulmonology Unit, Shaare Zedek Medical Center, Jerusalem, Israel
| | - V Molho-Pessach
- Department of Dermatology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| | - Y Tal
- Allergy and Clinical Immunology Unit, Department of Medicine, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| | - P Millman
- Pediatric Gastroenterology Unit, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| | - M Slae
- Pediatric Gastroenterology Unit, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| | - R Somech
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.,Pediatric Department A and Immunology Service, Jeffrey Modell Foundation Center, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Affiliated with Tel Aviv University, Tel Aviv, Israel
| | - O Toker
- Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.,Allergy and Clinical Immunology Unit, Shaare Zedek Medical Center, Jerusalem, Israel
| | - M Berger
- The Lautenberg Center for Immunology and Cancer Research, Institute of Medical Research Israel-Canada, Hebrew University-Hadassah Medical School, Jerusalem, Israel
| |
Collapse
|
14
|
Sitilertpisan P, Joseph L, Paungmali A, Paungmali U, Chunchai T. Investigation of the Contraction Ratio of Transversus Abdominis and Internal Oblique Muscles during Lumbopelvic Stability Test. Muscles Ligaments Tendons J 2020. [DOI: 10.32098/mltj.01.2020.10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- P. Sitilertpisan
- Department of Physical Therapy, Faculty of Associated Medical Sciences, Chiang Mai University, Chiangmai, Thailand
| | - L. Joseph
- School of Health Science, University of Brighton, East Sussex, United Kingdom
| | - A. Paungmali
- Department of Physical Therapy, Faculty of Associated Medical Sciences, Chiang Mai University, Chiangmai, Thailand
| | - U. Paungmali
- Department of Physical Therapy, Faculty of Associated Medical Sciences, Chiang Mai University, Chiangmai, Thailand
| | - T. Chunchai
- Department of Physiology, Faculty of Medicine, Chiang Mai University, Chiangmai, Thailand
| |
Collapse
|
15
|
Bougouin W, Dumas F, Lamhaut L, Marijon E, Carli P, Combes A, Pirracchio R, Aissaoui N, Karam N, Deye N, Sideris G, Beganton F, Jost D, Cariou A, Jouven X, Adnet F, Agostinucci JM, Aissaoui-Balanant N, Algalarrondo V, Alla F, Alonso C, Amara W, Annane D, Antoine C, Aubry P, Azoulay E, Beganton F, Benhamou D, Billon C, Bougouin W, Boutet J, Bruel C, Bruneval P, Cariou A, Carli P, Casalino E, Cerf C, Chaib A, Cholley B, Cohen Y, Combes A, Crahes M, Da Silva D, Das V, Demoule A, Denjoy I, Deye N, Dhonneur G, Diehl JL, Dinanian S, Domanski L, Dreyfuss D, Duboc D, Dubois-Rande JL, Dumas F, Empana JP, Extramiana F, Fartoukh M, Fieux F, Gabbas M, Gandjbakhch E, Geri G, Guidet B, Halimi F, Henry P, Hidden Lucet F, Jabre P, Jacob L, Joseph L, Jost D, Jouven X, Karam N, Kassim H, Lacotte J, Lahlou-Laforet K, Lamhaut L, Lanceleur A, Langeron O, Lavergne T, Lecarpentier E, Leenhardt A, Lellouche N, Lemiale V, Lemoine F, Linval F, Loeb T, Ludes B, Luyt CE, Maltret A, Mansencal N, Mansouri N, Marijon E, Marty J, Maury E, Maxime V, Megarbane B, Mekontso-Dessap A, Mentec H, Mira JP, Monnet X, Narayanan K, Ngoyi N, Perier MC, Piot O, Pirracchio R, Plaisance P, Plu I, Raux M, Revaux F, Ricard JD, Richard C, Riou B, Roussin F, Santoli F, Schortgen F, Sharifzadehgan A, Sideris G, Spaulding C, Teboul JL, Timsit JF, Tourtier JP, Tuppin P, Ursat C, Varenne O, Vieillard-Baron A, Voicu S, Wahbi K, Waldmann V. Extracorporeal cardiopulmonary resuscitation in out-of-hospital cardiac arrest: a registry study. Eur Heart J 2019; 41:1961-1971. [DOI: 10.1093/eurheartj/ehz753] [Citation(s) in RCA: 98] [Impact Index Per Article: 19.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/28/2018] [Revised: 03/26/2019] [Accepted: 10/01/2019] [Indexed: 11/13/2022] Open
Abstract
Abstract
Aims
Out-of-hospital cardiac arrest (OHCA) without return of spontaneous circulation (ROSC) despite conventional resuscitation is common and has poor outcomes. Adding extracorporeal membrane oxygenation (ECMO) to cardiopulmonary resuscitation (extracorporeal-CPR) is increasingly used in an attempt to improve outcomes.
Methods and results
We analysed a prospective registry of 13 191 OHCAs in the Paris region from May 2011 to January 2018. We compared survival at hospital discharge with and without extracorporeal-CPR and identified factors associated with survival in patients given extracorporeal-CPR. Survival was 8% in 525 patients given extracorporeal-CPR and 9% in 12 666 patients given conventional-CPR (P = 0.91). By adjusted multivariate analysis, extracorporeal-CPR was not associated with hospital survival [odds ratio (OR), 1.3; 95% confidence interval (95% CI), 0.8–2.1; P = 0.24]. By conditional logistic regression with matching on a propensity score (including age, sex, occurrence at home, bystander CPR, initial rhythm, collapse-to-CPR time, duration of resuscitation, and ROSC), similar results were found (OR, 0.8; 95% CI, 0.5–1.3; P = 0.41). In the extracorporeal-CPR group, factors associated with hospital survival were initial shockable rhythm (OR, 3.9; 95% CI, 1.5–10.3; P = 0.005), transient ROSC before ECMO (OR, 2.3; 95% CI, 1.1–4.7; P = 0.03), and prehospital ECMO implantation (OR, 2.9; 95% CI, 1.5–5.9; P = 0.002).
Conclusions
In a population-based registry, 4% of OHCAs were treated with extracorporeal-CPR, which was not associated with increased hospital survival. Early ECMO implantation may improve outcomes. The initial rhythm and ROSC may help select patients for extracorporeal-CPR.
Collapse
Affiliation(s)
- Wulfran Bougouin
- Paris Cardiovascular Research Center (PARCC), INSERM Unit 970, 56 rue Leblanc, 75787 Paris, France
- Medical-Surgical Intensive Care Unit, Ramsay Générale de Santé, Hôpital Privé Jacques Cartier, 6 Avenue du Noyer Lambert, 91300 Massy, France
- Paris Sudden Death Expertise Center, 56 rue Leblanc, 75787 Paris, France
- AfterROSC network, 27 Rue du Faubourg Saint-Jacques, 75014 Paris, France
| | - Florence Dumas
- Paris Cardiovascular Research Center (PARCC), INSERM Unit 970, 56 rue Leblanc, 75787 Paris, France
- Paris Sudden Death Expertise Center, 56 rue Leblanc, 75787 Paris, France
- Université Paris Descartes-Sorbonne Paris Cité, 12 Rue de l'École de Médecine, 75006 Paris, France
- Emergency Department, Cochin-Hotel-Dieu Hospital, APHP, 27 Rue du Faubourg Saint-Jacques, 75014 Paris, France
| | - Lionel Lamhaut
- Paris Cardiovascular Research Center (PARCC), INSERM Unit 970, 56 rue Leblanc, 75787 Paris, France
- Paris Sudden Death Expertise Center, 56 rue Leblanc, 75787 Paris, France
- AfterROSC network, 27 Rue du Faubourg Saint-Jacques, 75014 Paris, France
- Université Paris Descartes-Sorbonne Paris Cité, 12 Rue de l'École de Médecine, 75006 Paris, France
- Intensive Care Unit - SAMU 75, Necker-Enfants-Malades Hospital, APHP, 149 Rue de Sèvres, 75015 Paris, France
| | - Eloi Marijon
- Paris Cardiovascular Research Center (PARCC), INSERM Unit 970, 56 rue Leblanc, 75787 Paris, France
- Paris Sudden Death Expertise Center, 56 rue Leblanc, 75787 Paris, France
- Université Paris Descartes-Sorbonne Paris Cité, 12 Rue de l'École de Médecine, 75006 Paris, France
- Cardiology Department, Georges Pompidou European Hospital, AP-HP, 20 Rue Leblanc, 75015 Paris, France
| | - Pierre Carli
- Université Paris Descartes-Sorbonne Paris Cité, 12 Rue de l'École de Médecine, 75006 Paris, France
- Intensive Care Unit - SAMU 75, Necker-Enfants-Malades Hospital, APHP, 149 Rue de Sèvres, 75015 Paris, France
| | - Alain Combes
- Medical-Surgical Intensive Care Unit, iCAN, Institute of Cardiometabolism and Nutrition, Pitié-Salpétrière Hospital, APHP, 47-83 Boulevard de l'Hôpital, 75013 Paris, France
| | - Romain Pirracchio
- Université Paris Descartes-Sorbonne Paris Cité, 12 Rue de l'École de Médecine, 75006 Paris, France
- Surgical ICU, Georges Pompidou European Hospital, AP-HP, 20 Rue Leblanc, 75015 Paris, France
| | - Nadia Aissaoui
- Paris Cardiovascular Research Center (PARCC), INSERM Unit 970, 56 rue Leblanc, 75787 Paris, France
- Paris Sudden Death Expertise Center, 56 rue Leblanc, 75787 Paris, France
- AfterROSC network, 27 Rue du Faubourg Saint-Jacques, 75014 Paris, France
- Université Paris Descartes-Sorbonne Paris Cité, 12 Rue de l'École de Médecine, 75006 Paris, France
- Medical ICU, Georges Pompidou European Hospital, AP-HP, 20 Rue Leblanc, 75015 Paris, France
| | - Nicole Karam
- Paris Cardiovascular Research Center (PARCC), INSERM Unit 970, 56 rue Leblanc, 75787 Paris, France
- Paris Sudden Death Expertise Center, 56 rue Leblanc, 75787 Paris, France
- Université Paris Descartes-Sorbonne Paris Cité, 12 Rue de l'École de Médecine, 75006 Paris, France
- Cardiology Department, Georges Pompidou European Hospital, AP-HP, 20 Rue Leblanc, 75015 Paris, France
| | - Nicolas Deye
- AfterROSC network, 27 Rue du Faubourg Saint-Jacques, 75014 Paris, France
- Medical ICU, Lariboisière Hospital, AP-HP, 2 Rue Ambroise Paré, 75010 Paris, France
| | - Georgios Sideris
- Cardiology Department, Lariboisière Hospital, AP-HP, 2 Rue Ambroise Paré, 75010 Paris, France
| | - Frankie Beganton
- Paris Cardiovascular Research Center (PARCC), INSERM Unit 970, 56 rue Leblanc, 75787 Paris, France
- Paris Sudden Death Expertise Center, 56 rue Leblanc, 75787 Paris, France
| | - Daniel Jost
- Paris Cardiovascular Research Center (PARCC), INSERM Unit 970, 56 rue Leblanc, 75787 Paris, France
- Paris Sudden Death Expertise Center, 56 rue Leblanc, 75787 Paris, France
- Brigade de Sapeurs Pompiers de Paris (BSPP), 1 Place Jules Renard, 75017 Paris, France
| | - Alain Cariou
- Paris Cardiovascular Research Center (PARCC), INSERM Unit 970, 56 rue Leblanc, 75787 Paris, France
- Paris Sudden Death Expertise Center, 56 rue Leblanc, 75787 Paris, France
- AfterROSC network, 27 Rue du Faubourg Saint-Jacques, 75014 Paris, France
- Université Paris Descartes-Sorbonne Paris Cité, 12 Rue de l'École de Médecine, 75006 Paris, France
- Medical Intensive Care Unit, Cochin Hospital, APHP, 27 Rue du Faubourg Saint-Jacques, 75014 Paris, France
| | - Xavier Jouven
- Paris Cardiovascular Research Center (PARCC), INSERM Unit 970, 56 rue Leblanc, 75787 Paris, France
- Paris Sudden Death Expertise Center, 56 rue Leblanc, 75787 Paris, France
- Université Paris Descartes-Sorbonne Paris Cité, 12 Rue de l'École de Médecine, 75006 Paris, France
- Cardiology Department, Georges Pompidou European Hospital, AP-HP, 20 Rue Leblanc, 75015 Paris, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Sanmamed N, Glicksman R, Heaton J, Herrera-Caceres J, Joseph L, Hansen A, Chung P, Finelli A, Fleshner N, Berlin A. Use of Combined Hormone Therapy with Post-Operative Radiation Treatment for Prostate Cancer: Impact of Randomized Trials On Clinical Practice. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.1768] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
17
|
Hopman WM, Berger C, Joseph L, Morin SN, Towheed T, Anastassiades T, Adachi JD, Hanley DA, Prior JC, Goltzman D. Longitudinal assessment of health-related quality of life in osteoporosis: data from the population-based Canadian Multicentre Osteoporosis Study. Osteoporos Int 2019; 30:1635-1644. [PMID: 31069440 DOI: 10.1007/s00198-019-05000-y] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/04/2019] [Accepted: 04/22/2019] [Indexed: 01/22/2023]
Abstract
UNLABELLED Little is known about the association between health-related quality of life (HRQOL) and osteoporosis in the absence of fracture, and how HRQOL may change over time. This study provides evidence of substantially reduced HRQOL in women and men with self-reported and/or BMD-confirmed osteoporosis, even in the absence of fragility fracture. INTRODUCTION Fragility fractures have a detrimental effect on the health-related quality of life (HRQOL) of those with osteoporosis. Less is known about the association between HRQOL and osteoporosis in the absence of fracture. METHODS Canadian Multicentre Osteoporosis Study participants completed the SF-36, a detailed health questionnaire and measures of bone mineral density (BMD) at baseline and follow-up. We report the results of participants ≥ 50 years with 10-year follow-up. Self-reported osteoporosis at baseline and BMD-based osteoporosis at follow-up were ascertained. Multivariable linear regression models were developed for baseline SF-36 domains, component summaries, and change over time, adjusting for relevant baseline information. RESULTS Baseline data were available for 5266 women and 2112 men. Women in the osteoporosis group had substantially lower SF-36 baseline scores, particularly in the physically oriented domains, than those without osteoporosis. A similar but attenuated pattern was evident for the men. After 10-year follow-up (2797 women and 1023 men), most domain scores dropped for women and men regardless of osteoporosis status, with the exception of mentally-oriented ones. In general, a fragility fracture was associated with lower SF-36 scores and larger declines over time. CONCLUSIONS This study provides evidence of substantially reduced HRQOL in women and men with self-reported and/or BMD-confirmed osteoporosis, even in the absence of fragility fracture. HRQOL should be thoroughly investigated even prior to fracture, to develop appropriate interventions for all stages of the disease.
Collapse
Affiliation(s)
- W M Hopman
- Kingston General Health Research Institute, Kingston Health Sciences Centre, Kingston, Ontario, Canada.
- Department of Public Health Sciences, Faculty of Medicine, Queen's University, Kingston, Ontario, Canada.
| | - C Berger
- Research Institute of the McGill University Health Centre, Montreal, QC, Canada
| | - L Joseph
- Department of Epidemiology and Biostatistics, McGill University, Montreal, QC, Canada
| | - S N Morin
- Department of Medicine, McGill University, Montréal, QC, Canada
| | - T Towheed
- Division of Rheumatology, Department of Medicine, Queen's University, Kingston, ON, Canada
| | - T Anastassiades
- Division of Rheumatology, Department of Medicine, Queen's University, Kingston, ON, Canada
| | - J D Adachi
- Department of Medicine, McMaster University, Hamilton, ON, Canada
| | - D A Hanley
- McCaig Institute for Bone & Joint Health, University of Calgary, Calgary, AB, Canada
| | - J C Prior
- Department of Medicine/Endocrinology, University of British Columbia, Vancouver, BC, Canada
| | - D Goltzman
- Department of Medicine, McGill University, Montréal, QC, Canada
| | | |
Collapse
|
18
|
Honsel V, Khimoud D, Ranque B, Offredo L, Joseph L, Pouchot J, Arlet J. Différences phénotypiques entre patients drépanocytaires adultes d’origine sub-Saharienne nés en France métropolitaine et nés en Afrique sub-Saharienne. Rev Med Interne 2019. [DOI: 10.1016/j.revmed.2019.03.059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
19
|
Dougherty U, Mustafi R, Haider HI, Khalil A, Souris JS, Joseph L, Hart J, Konda VJ, Zhang W, Pekow J, Li YC, Bissonnette M. Losartan and Vitamin D Inhibit Colonic Tumor Development in a Conditional Apc-Deleted Mouse Model of Sporadic Colon Cancer. Cancer Prev Res (Phila) 2019; 12:433-448. [PMID: 31088824 DOI: 10.1158/1940-6207.capr-18-0380] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2018] [Revised: 04/02/2019] [Accepted: 05/06/2019] [Indexed: 12/20/2022]
Abstract
Colorectal cancer is a leading cause of cancer deaths. The renin-angiotensin system (RAS) is upregulated in colorectal cancer, and epidemiologic studies suggest RAS inhibitors reduce cancer risk. Because vitamin D (VD) receptor negatively regulates renin, we examined anticancer efficacy of VD and losartan (L), an angiotensin receptor blocker. Control Apc+/LoxP mice and tumor-forming Apc+/LoxP Cdx2P-Cre mice were randomized to unsupplemented Western diet (UN), or diets supplemented with VD, L, or VD+L, the latter to assess additive or synergistic effects. At 6 months, mice were killed. Plasma Ca2+, 25(OH)D3, 1α, 25(OH)2D3, renin, and angiotensin II (Ang II) were quantified. Colonic transcripts were assessed by qPCR and proteins by immunostaining and blotting. Cancer incidence and tumor burden were significantly lower in Cre+ VD and Cre+ L, but not in the Cre+ VD+L group. In Apc+/LoxP mice, VD increased plasma 1,25(OH)2D3 and colonic VDR. In Apc+/LoxP-Cdx2P-Cre mice, plasma renin and Ang II, and colonic tumor AT1, AT2, and Cyp27B1 were increased and VDR downregulated. L increased, whereas VD decreased plasma renin and Ang II in Cre+ mice. VD or L inhibited tumor development, while exerting differential effects on plasma VD metabolites and RAS components. We speculate that AT1 is critical for tumor development, whereas RAS suppression plays a key role in VD chemoprevention. When combined with L, VD no longer increases active VD and colonic VDR in Cre- mice nor suppresses renin and Ang II in Cre+ mice, likely contributing to lack of chemopreventive efficacy of the combination.
Collapse
Affiliation(s)
| | - Reba Mustafi
- Department of Medicine, University of Chicago, Chicago, Illinois
| | - Haider I Haider
- Department of Medicine, University of Chicago, Chicago, Illinois
| | | | - Jeffrey S Souris
- Department of Radiology, University of Chicago, Chicago, Illinois
| | - Loren Joseph
- Department of Pathology, Beth Israel, Harvard Medical School, Boston, Massachusetts
| | - John Hart
- Department of Pathology, University of Chicago, Chicago, Illinois
| | - Vani J Konda
- Department of Medicine, University of Chicago, Chicago, Illinois
| | - Wei Zhang
- Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois
| | - Joel Pekow
- Department of Medicine, University of Chicago, Chicago, Illinois
| | - Yan Chun Li
- Department of Medicine, University of Chicago, Chicago, Illinois
| | - Marc Bissonnette
- Department of Medicine, University of Chicago, Chicago, Illinois.
| |
Collapse
|
20
|
Joseph L, Sundaramurthy A, Berlin A, Helou J, Menard C, Warde P, Catton C, Lao B, Bayley A, Rink A, Beiki-Ardakani A, Chung P. PV-0147 MRI-guided salvage HDR brachytherapy for locally recurrent prostate cancer. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)30567-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
21
|
Ragon BK, Odenike O, Baer MR, Stock W, Borthakur G, Patel K, Han L, Chen H, Ma H, Joseph L, Zhao Y, Baggerly K, Konopleva M, Jain N. Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study. Clin Lymphoma Myeloma Leuk 2019; 19:431-440.e13. [PMID: 31056348 DOI: 10.1016/j.clml.2019.03.015] [Citation(s) in RCA: 41] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/30/2018] [Revised: 02/25/2019] [Accepted: 03/17/2019] [Indexed: 10/27/2022]
Abstract
BACKGROUND With proven single-agent activity and favorable toxicity profile of MEK-1/2 inhibition in advanced leukemia, investigation into combination strategies to overcome proposed resistance pathways is warranted. Resistance to MEK inhibition is secondary to upstream hyperactivation of RAS/RAF or activation of the PI3K/PTEN/AKT/mTOR pathway. This phase II multi-institution Cancer Therapy Evaluation Program-sponsored study was conducted to determine efficacy and safety of the combination of the ATP-competitive pan-AKT inhibitor GSK2141795, targeting the PI3K/AKT pathway, and the MEK inhibitor trametinib in RAS-mutated relapsed/refractory acute myeloid leukemia (AML). PATIENTS AND METHODS The primary objective was to determine the proportion of patients achieving a complete remission. Secondary objectives included assessment of toxicity profile and biologic effects of this combination. Twenty-three patients with RAS-mutated AML received the combination. Two dose levels were explored (dose level 1: 2 mg trametinib, 25 mg GSK2141795 and dose level 2: 1.5 mg trametinib, 50 mg GSK2141795). RESULTS Dose level 1 was identified as the recommended phase II dose. No complete remissions were identified in either cohort. Minor responses were recognized in 5 (22%) patients. The most common drug-related toxicities included rash and diarrhea, with dose-limiting toxicities of mucositis and colitis. Longitudinal correlative assessment of the modulation of MEK and AKT pathways using reverse phase protein array and phospho-flow analysis revealed significant and near significant down-modulation of pERK and pS6, respectively. Combined MEK and AKT inhibition had no clinical activity in patients with RAS-mutated AML. CONCLUSION Further investigation is required to explore the discrepancy between the activity of this combination on leukemia cells and the lack of clinical efficacy.
Collapse
Affiliation(s)
- Brittany Knick Ragon
- Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC
| | - Olatoyosi Odenike
- Department of Medicine, University of Chicago Medical Center, Chicago, IL
| | - Maria R Baer
- University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD
| | - Wendy Stock
- Department of Medicine, University of Chicago Medical Center, Chicago, IL
| | - Gautam Borthakur
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Keyur Patel
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Lina Han
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Helen Chen
- Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD
| | - Helen Ma
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Loren Joseph
- Division of Clinical Pathology, Beth Israel Deaconess Medical Center, Boston, MA
| | - Yang Zhao
- Department of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, TX
| | - Keith Baggerly
- Department of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, TX
| | - Marina Konopleva
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Nitin Jain
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
| |
Collapse
|
22
|
Khan Z, Ahmad S, Jeragh A, Alfouzan W, Al Foudri H, Hassan N, Asadzadeh M, Joseph L, Varghese S. First isolation of Ascotricha chartarum from bronchoalveolar lavage of two patients with pulmonary infections. New Microbes New Infect 2018; 28:11-16. [PMID: 30766685 PMCID: PMC6363919 DOI: 10.1016/j.nmni.2018.12.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2018] [Revised: 12/18/2018] [Accepted: 12/19/2018] [Indexed: 11/12/2022] Open
Abstract
Ascotricha chartarum is a rare human pathogen. We describe the isolation and characterization of A. chartarum from bronchoalveolar lavage samples of two patients with underlying pulmonary infections. The identity of both isolates was established by typical phenotypic characteristics and by sequencing of the internal transcribed spacer region and D1/D2 domains of recombinant DNA and β-tubulin gene fragment. The demonstration of branched, septate hyphae in direct microscopic examination of both the specimens and isolation of the fungus in pure cultures suggest its aetiologic role in the disease process. Because of phenotypic similarities of A. chartarum with Chaetomium spp. and other Chaetomium-like fungi, the application of molecular methods is needed for its accurate identification. Although in the absence of histopathologic evidence the aetiologic role of A. chartarum could not be established unequivocally, nonetheless, in view of the rarity of its isolation from clinical specimens and demonstration of hyphal elements in bronchoalveolar lavage sample, this report assumes considerable significance. It serves to create awareness about environmental fungi that previously have missed attention but may play a role in respiratory infections.
Collapse
Affiliation(s)
- Z Khan
- Department of Microbiology, Faculty of Medicine, Kuwait University, Kuwait
| | - S Ahmad
- Department of Microbiology, Faculty of Medicine, Kuwait University, Kuwait
| | - A Jeragh
- Department of Microbiology, , Al Adan Hospital, Kuwait
| | - W Alfouzan
- Department of Microbiology, Faculty of Medicine, Kuwait University, Kuwait
| | - H Al Foudri
- Critical Care and ECMO Unit, Anesthesia Department, Al Adan Hospital, Kuwait
| | - N Hassan
- Department of Microbiology, , Al Adan Hospital, Kuwait
| | - M Asadzadeh
- Department of Microbiology, Faculty of Medicine, Kuwait University, Kuwait
| | - L Joseph
- Department of Microbiology, Faculty of Medicine, Kuwait University, Kuwait
| | - S Varghese
- Department of Microbiology, Faculty of Medicine, Kuwait University, Kuwait
| |
Collapse
|
23
|
Jeragh A, Ahmad S, Khan Z, Tarazi RY, Ajmi S, Joseph L, Varghese S, Vayalil S. Subcutaneous phaeohyphomycosis caused by Amesia atrobrunnea in Kuwait. J Mycol Med 2018; 29:193-197. [PMID: 30446389 DOI: 10.1016/j.mycmed.2018.10.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2018] [Revised: 09/10/2018] [Accepted: 10/29/2018] [Indexed: 11/26/2022]
Abstract
The recently described genus Amesia encompasses four species but only Amesia atrobrunnea (=Chaetomium atrobrunneum) is known to be pathogenic to humans. Here, we describe a case of subcutaneous phaeohyphomycosis in Kuwait in an apparently immunocompetent patient diagnosed by direct microscopy of the infected tissue and culture. The identity of A. atrobrunnea was established by typical morphological characteristics and by sequencing of internally transcribed spacer (ITS) region and D1/D2 domains of rDNA. To the best of our knowledge, this is the first report documenting etiologic role of this species in causing a locally invasive subcutaneous infection.
Collapse
Affiliation(s)
- A Jeragh
- Departments of Microbiology, Al Adan Hospital, Kuwait
| | - S Ahmad
- Department of Microbiology, Kuwait
| | - Z Khan
- Department of Microbiology, Kuwait; Mycology Reference Laboratory, Faculty of Medicine, Kuwait University, Kuwait.
| | - R Y Tarazi
- Cardiac surgery, Al Adan Hospital, Kuwait
| | - S Ajmi
- Departments of Microbiology, Al Adan Hospital, Kuwait
| | - L Joseph
- Department of Microbiology, Kuwait
| | | | - S Vayalil
- Mycology Reference Laboratory, Faculty of Medicine, Kuwait University, Kuwait
| |
Collapse
|
24
|
Affiliation(s)
- L Joseph
- Imperial College London, London, UK
| | - S Ismail
- Imperial College London, London, UK
| | | | - M Gunst
- Sydney Children's Hospital Network, Sydney, Australia
| | | | - M Harris
- Imperial College London, London, UK
| | - A Abbara
- Imperial College London, London, UK
| |
Collapse
|
25
|
Parikh S, Murray L, Kenning L, Bottomley D, Din O, Dixit S, Ferguson C, Handforth C, Joseph L, Mokhtar D, White L, Wright G, Henry A. Real-world Outcomes and Factors Predicting Survival and Completion of Radium 223 in Metastatic Castrate-resistant Prostate Cancer. Clin Oncol (R Coll Radiol) 2018; 30:548-555. [DOI: 10.1016/j.clon.2018.06.004] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2018] [Revised: 05/16/2018] [Accepted: 05/20/2018] [Indexed: 01/04/2023]
|
26
|
Wilcox RL, Adem PV, Afshinnekoo E, Atkinson JB, Burke LW, Cheung H, Dasgupta S, DeLaGarza J, Joseph L, LeGallo R, Lew M, Lockwood CM, Meiss A, Norman J, Markwood P, Rizvi H, Shane-Carson KP, Sobel ME, Suarez E, Tafe LJ, Wang J, Haspel RL. The Undergraduate Training in Genomics (UTRIG) Initiative: early & active training for physicians in the genomic medicine era. Per Med 2018; 15:199-208. [PMID: 29843583 DOI: 10.2217/pme-2017-0077] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Genomic medicine is transforming patient care. However, the speed of development has left a knowledge gap between discovery and effective implementation into clinical practice. Since 2010, the Training Residents in Genomics (TRIG) Working Group has found success in building a rigorous genomics curriculum with implementation tools aimed at pathology residents in postgraduate training years 1-4. Based on the TRIG model, the interprofessional Undergraduate Training in Genomics (UTRIG) Working Group was formed. Under the aegis of the Undergraduate Medical Educators Section of the Association of Pathology Chairs and representation from nine additional professional societies, UTRIG's collaborative goal is building medical student genomic literacy through development of a ready-to-use genomics curriculum. Key elements to the UTRIG curriculum are expert consensus-driven objectives, active learning methods, rigorous assessment and integration.
Collapse
Affiliation(s)
- Rebecca L Wilcox
- Department of Pathology and Laboratory Medicine and Department of Pediatrics, University of Vermont Medical Center, Larner College of Medicine, University of Vermont, Burlington, VT, 05401, USA
| | - Patricia V Adem
- Department of Pathology, New York Medical College School of Medicine, Valhalla, NY, 10595, USA
| | - Ebrahim Afshinnekoo
- Department of Pathology, New York Medical College School of Medicine, Valhalla, NY, 10595, USA
| | - James B Atkinson
- Department of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN, 37232, USA
| | - Leah W Burke
- Department of Pathology and Laboratory Medicine and Department of Pediatrics, University of Vermont Medical Center, Larner College of Medicine, University of Vermont, Burlington, VT, 05401, USA
| | - Hoiwan Cheung
- Department of Pathology and Laboratory Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH/Geisel School of Medicine at Dartmouth, Hanover, NH, 03755, USA
| | - Shoumita Dasgupta
- Department of Medicine, Biomedical Genetics Section, Boston University School of Medicine, Boston, MA, 02118, USA
| | - Julia DeLaGarza
- Department of Pathology, New York Medical College School of Medicine, Valhalla, NY, 10595, USA
| | - Loren Joseph
- Department of Pathology, Beth Israel Deaconess Medical Center & Harvard Medical School, Boston, MA, 02115, USA
| | - Robin LeGallo
- Department of Pathology, University of Virginia School of Medicine, Charlottesville, VA, 22908, USA
| | - Madelyn Lew
- Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, 48109, USA
| | - Christina M Lockwood
- Department of Laboratory Medicine, University of Washington School of Medicine, Seattle, WA, 98195, USA
| | - Alice Meiss
- Department of Pathology, University of Virginia School of Medicine, Charlottesville, VA, 22908, USA
| | | | | | - Hasan Rizvi
- Institue of Health Sciences Education, Barts and the London School of Medicine and Dentistry, Queen Mary, University of London, London, E1 2AD, UK
| | - Kate P Shane-Carson
- Division of Human Genetics, Department of Internal Medicine, Ohio State University Comprehensive Cancer Center, Columbus, OH, 43210, USA
| | - Mark E Sobel
- American Society for Investigative Pathology, Rockville, MD, 20852, USA
| | - Eric Suarez
- Pathology Department, Uniformed Services University, Bethesda, MD, 20814, USA
| | - Laura J Tafe
- Department of Pathology and Laboratory Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH/Geisel School of Medicine at Dartmouth, Hanover, NH, 03755, USA
| | - Jason Wang
- Department of Pathology, UT Southwestern Medical Center, Dallas, TX, 75390, USA
| | - Richard L Haspel
- Department of Pathology, Beth Israel Deaconess Medical Center & Harvard Medical School, Boston, MA, 02115, USA
| |
Collapse
|
27
|
Sanchez-Villavicencio ML, Elamer N, Joseph L, Saleem A, Hall B, Harris CS, Cuerrier A, Arnason JT, Haddad PS. Non-polar solvent fractions of Oplopanax horridus stimulate muscle glucose uptake and inhibit hepatocellular glucose-6-phosphatase enzyme activity. Am J Transl Res 2018. [DOI: 10.1055/s-0038-1644932] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- ML Sanchez-Villavicencio
- CIHR Team in Aboriginal Antidiabetic Medicines
- Département de pharmacologie et physiologie, Université de Montréal, Montréal, QUEBEC, Canada
| | - N Elamer
- CIHR Team in Aboriginal Antidiabetic Medicines
- Département de pharmacologie et physiologie, Université de Montréal, Montréal, QUEBEC, Canada
| | - L Joseph
- CIHR Team in Aboriginal Antidiabetic Medicines
- Département de sciences biologiques, Université de Montréal, Montréal, QUEBEC, Canada
| | - A Saleem
- CIHR Team in Aboriginal Antidiabetic Medicines
- Department of Biology, School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada
| | - B Hall
- CIHR Team in Aboriginal Antidiabetic Medicines
- Department of Biology, School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada
| | - CS Harris
- CIHR Team in Aboriginal Antidiabetic Medicines
- Department of Biology, School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada
| | - A Cuerrier
- CIHR Team in Aboriginal Antidiabetic Medicines
- Département de sciences biologiques, Université de Montréal, Montréal, QUEBEC, Canada
| | - JT Arnason
- CIHR Team in Aboriginal Antidiabetic Medicines
- Department of Biology, School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada
| | - PS Haddad
- CIHR Team in Aboriginal Antidiabetic Medicines
- Département de pharmacologie et physiologie, Université de Montréal, Montréal, QUEBEC, Canada
| |
Collapse
|
28
|
Salem A, Gorman D, Mistry H, Joseph L, Shah R, Valentine H, Jackson A, West C, Faivre-Finn C, O'Connor J, Asselin M. OC-0267: Technical and biological validation of hypoxia PET imaging using [18F]fluroazomycin (FAZA) in NSCLC. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)30577-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
29
|
Cessna JT, Fitzgerald R, Zimmerman BE, Laureano-Pérez L, Bergeron DE, van Wyngaardt F, Smith M, Jackson T, Howe B, da Silva CJ, Iwahara A, da Cruz PAL, Zhang M, Liu H, Liang J, Fréchou C, Bobin C, Cassette P, Kossert K, Nähle O, Marganiec-Gałązka J, Joseph L, Ravindra A, Kulkarni DN, Yunoki A, Sato Y, Lee KB, Lee JM, Agung, Dziel T, Listkowska A, Tymiński Z, Sahagia M, Antohe A, Ioan MR, Luca A, Krivosek M, Ometakova J, Javornik A, Zalesakova M, García-Toraño Martinez E, Roteta M, Mejuto M, Nedjadi Y, Juget F, Yuan MC, Yeh CY, Yeltepe E, Dirican A, Keightley J, Pearce A. Results of an international comparison of activity measurements of 68Ge. Appl Radiat Isot 2018; 134:385-390. [PMID: 29248210 PMCID: PMC10996930 DOI: 10.1016/j.apradiso.2017.10.052] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2017] [Revised: 10/30/2017] [Accepted: 10/30/2017] [Indexed: 11/25/2022]
Abstract
An international key comparison, identifier CCRI(II)-K2.Ge-68, has been performed. The National Institute of Standards and Technology (NIST) served as the pilot laboratory, distributing aliquots of a 68Ge/68Ga solution. Results for the activity concentration, CA, of 68Ge at a reference date of 12h00 UTC 14 November 2014 were submitted by 17 laboratories, encompassing many variants of coincidence methods and liquid-scintillation counting methods. The first use of 4π(Cherenkov)β-γ coincidence and anticoincidence methods in an international comparison is reported. One participant reported results by secondary methods only. Two results, both utilizing pure liquid-scintillation methods, were identified as outliers. Evaluation using the Power-Moderated Mean method results in a proposed Comparison Reference Value (CRV) of 621.7(11)kBqg-1, based on 14 results. The degrees of equivalence and their associated uncertainties are evaluated for each participant. Several participants submitted 3.6mL ampoules to the BIPM to link the comparison to the International Reference System (SIR) which may lead to the evaluation of a Key Comparison Reference Value and associated degrees of equivalence.
Collapse
Affiliation(s)
- J T Cessna
- Physical Measurements Laboratory, National Institute of Standards and Technology, Gaithersburg, MD, USA.
| | - R Fitzgerald
- Physical Measurements Laboratory, National Institute of Standards and Technology, Gaithersburg, MD, USA
| | - B E Zimmerman
- Physical Measurements Laboratory, National Institute of Standards and Technology, Gaithersburg, MD, USA
| | - L Laureano-Pérez
- Physical Measurements Laboratory, National Institute of Standards and Technology, Gaithersburg, MD, USA
| | - D E Bergeron
- Physical Measurements Laboratory, National Institute of Standards and Technology, Gaithersburg, MD, USA
| | - F van Wyngaardt
- Australian Nuclear Science and Technology Organisation, Lucas Heights, Australia
| | - M Smith
- Australian Nuclear Science and Technology Organisation, Lucas Heights, Australia
| | - T Jackson
- Australian Nuclear Science and Technology Organisation, Lucas Heights, Australia
| | - B Howe
- Australian Nuclear Science and Technology Organisation, Lucas Heights, Australia
| | - C J da Silva
- Laboratório Nacional de Metrologia das Radiações Ionizantes, Instituto de Radioproteção e Dosimetria, Rio de Janeiro, Brazil
| | - A Iwahara
- Laboratório Nacional de Metrologia das Radiações Ionizantes, Instituto de Radioproteção e Dosimetria, Rio de Janeiro, Brazil
| | - P A L da Cruz
- Laboratório Nacional de Metrologia das Radiações Ionizantes, Instituto de Radioproteção e Dosimetria, Rio de Janeiro, Brazil
| | - M Zhang
- National Institute of Metrology, Beijing, China
| | - H Liu
- National Institute of Metrology, Beijing, China
| | - J Liang
- National Institute of Metrology, Beijing, China
| | - C Fréchou
- Laboratoire national de métrologie et d'essais - Laboratoire national Henri Becquerel, Gif-sur-Yvette cedex, France
| | - C Bobin
- Laboratoire national de métrologie et d'essais - Laboratoire national Henri Becquerel, Gif-sur-Yvette cedex, France
| | - P Cassette
- Laboratoire national de métrologie et d'essais - Laboratoire national Henri Becquerel, Gif-sur-Yvette cedex, France
| | - K Kossert
- Physikalisch-Technische Bundesanstalt, Braunschweig, Germany
| | - O Nähle
- Physikalisch-Technische Bundesanstalt, Braunschweig, Germany
| | | | - L Joseph
- Bhabha Atomic Research Centre, Mumbai, India
| | - A Ravindra
- Bhabha Atomic Research Centre, Mumbai, India
| | | | - A Yunoki
- National Metrology Institute of Japan, AIST, Tsukuba, Japan
| | - Y Sato
- National Metrology Institute of Japan, AIST, Tsukuba, Japan
| | - K B Lee
- Korea Research Institute of Standards and Science, Daejeon, Republic of Korea
| | - J M Lee
- Korea Research Institute of Standards and Science, Daejeon, Republic of Korea
| | - Agung
- Korea Research Institute of Standards and Science, Daejeon, Republic of Korea
| | - T Dziel
- National Centre for Nuclear Research Radioisotope Centre POLATOM, Otwock, Poland
| | - A Listkowska
- National Centre for Nuclear Research Radioisotope Centre POLATOM, Otwock, Poland
| | - Z Tymiński
- National Centre for Nuclear Research Radioisotope Centre POLATOM, Otwock, Poland
| | - M Sahagia
- National Institute of Research and Development for Physics and Nuclear Engineering "Horia Hulubei", Bucarest - Magurele, Romania
| | - A Antohe
- National Institute of Research and Development for Physics and Nuclear Engineering "Horia Hulubei", Bucarest - Magurele, Romania
| | - M-R Ioan
- National Institute of Research and Development for Physics and Nuclear Engineering "Horia Hulubei", Bucarest - Magurele, Romania
| | - A Luca
- National Institute of Research and Development for Physics and Nuclear Engineering "Horia Hulubei", Bucarest - Magurele, Romania
| | - M Krivosek
- Slovenský Metrologický Ústav, Bratislava, Slovakia
| | - J Ometakova
- Slovenský Metrologický Ústav, Bratislava, Slovakia
| | - A Javornik
- Slovenský Metrologický Ústav, Bratislava, Slovakia
| | - M Zalesakova
- Slovenský Metrologický Ústav, Bratislava, Slovakia
| | | | - M Roteta
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Madrid, Spain
| | - M Mejuto
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Madrid, Spain
| | - Y Nedjadi
- Institut Universitaire de Radiophysique Appliquée, Lausanne, Switzerland
| | - F Juget
- Institut Universitaire de Radiophysique Appliquée, Lausanne, Switzerland
| | - M-C Yuan
- Institute of Nuclear Energy Research, Taoyuan County, Taiwan
| | - C Y Yeh
- Institute of Nuclear Energy Research, Taoyuan County, Taiwan
| | - E Yeltepe
- Turkish Atomic Energy Authority, Lodumlu - Ankara, Turkey
| | - A Dirican
- Turkish Atomic Energy Authority, Lodumlu - Ankara, Turkey
| | - J Keightley
- National Physical Laboratory, Teddington, United Kingdom
| | - A Pearce
- National Physical Laboratory, Teddington, United Kingdom
| |
Collapse
|
30
|
Bissonnette BM, Dougherty U, Mustafi R, Haider HI, Joseph L, Souris J, Hart JA, Pewkow JR, LI YC. CXCR4 inhibitor, MSX‐122 suppresses AOM‐induced colon cancer in Apc+/Min mouse. FASEB J 2018. [DOI: 10.1096/fasebj.2018.32.1_supplement.677.4] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
31
|
Joseph L. Telomere Diagnostics for Pancreatic Neoplasms and Cysts. J Mol Diagn 2018; 20:31-33. [DOI: 10.1016/j.jmoldx.2017.11.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2017] [Revised: 10/29/2017] [Accepted: 11/02/2017] [Indexed: 11/17/2022] Open
|
32
|
Affiliation(s)
- B G Baker
- 1 Department of Burns & Plastic Surgery, University Hospital South Manchester, Wythenshawe, UK
| | - L Joseph
- 2 Department of Pathology, University Hospital South Manchester, Wythenshawe, UK
| | - A Mishra
- 1 Department of Burns & Plastic Surgery, University Hospital South Manchester, Wythenshawe, UK
| |
Collapse
|
33
|
Shah B, Preset I, Basnet M, Joseph L, Bishop P, Quinn A. 42: An audit of the frequency of immunochemical expression of CDX2 within lung carcinomas. Lung Cancer 2017. [DOI: 10.1016/s0169-5002(17)30092-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
34
|
Vanderlaan P, Rangachari D, Mockus S, Spotlow V, Reddi H, Malcom J, Huberman M, Joseph L, Kobayashi S, Costa D. P1.02-031 Mutations in TP53, PIK3CA, PTEN and Other Genes in EGFR Mutated Lung Cancers: Correlation with Clinical Outcomes. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2016.11.614] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
35
|
Basnet M, Quinn A, Noor H, Rana D, Thiryayi S, Shelton D, Al-Habba S, Narine N, McGrath S, Chandran U, Doran H, Joseph L, Bishop P, Chaturvedi A, Ganjifrockwala A, Paiva-Correia A, Saravana R, Nasir N, Nonaka D, Wallace A, Crosbie P, Bayman N, Blackhall F. 53: A survey of regional practice affecting small sample diagnosis and tissue managment of lung carcinoma samples, with development of a local guideline. Lung Cancer 2017. [DOI: 10.1016/s0169-5002(17)30103-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
36
|
Larivée N, Suissa S, Eberg M, Joseph L, Eisenberg MJ, Abenhaim HA, Filion KB. Drospirenone-containing combined oral contraceptives and the risk of arterial thrombosis: a population-based nested case-control study. BJOG 2016; 124:1672-1679. [DOI: 10.1111/1471-0528.14358] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/16/2016] [Indexed: 11/29/2022]
Affiliation(s)
- N Larivée
- Center for Clinical Epidemiology; Lady Davis Institute; Jewish General Hospital; Montreal Quebec Canada
- Department of Epidemiology, Biostatistics and Occupational Health; McGill University; Montreal Quebec Canada
| | - S Suissa
- Center for Clinical Epidemiology; Lady Davis Institute; Jewish General Hospital; Montreal Quebec Canada
- Department of Epidemiology, Biostatistics and Occupational Health; McGill University; Montreal Quebec Canada
- Division of Clinical Epidemiology; Department of Medicine; McGill University; Montreal Quebec Canada
| | - M Eberg
- Center for Clinical Epidemiology; Lady Davis Institute; Jewish General Hospital; Montreal Quebec Canada
| | - L Joseph
- Department of Epidemiology, Biostatistics and Occupational Health; McGill University; Montreal Quebec Canada
- Division of Clinical Epidemiology; McGill University Health Centre; Montreal Quebec Canada
| | - MJ Eisenberg
- Center for Clinical Epidemiology; Lady Davis Institute; Jewish General Hospital; Montreal Quebec Canada
- Department of Epidemiology, Biostatistics and Occupational Health; McGill University; Montreal Quebec Canada
- Division of Cardiology; Jewish General Hospital; McGill University; Montreal Quebec Canada
| | - HA Abenhaim
- Center for Clinical Epidemiology; Lady Davis Institute; Jewish General Hospital; Montreal Quebec Canada
- Department of Obstetrics and Gynecology; Jewish General Hospital; McGill University; Montreal Quebec Canada
| | - KB Filion
- Center for Clinical Epidemiology; Lady Davis Institute; Jewish General Hospital; Montreal Quebec Canada
- Department of Epidemiology, Biostatistics and Occupational Health; McGill University; Montreal Quebec Canada
- Division of Clinical Epidemiology; Department of Medicine; McGill University; Montreal Quebec Canada
| |
Collapse
|
37
|
Lowensteyn I, Berberian V, Joseph L, Belisle P, Grover S. USING THE WORKPLACE TO OPTIMIZE HEART HEALTH. THE 1-YEAR RESULTS OF THE MERCK CANADA EMPLOYEE WELLNESS PROGRAM. Can J Cardiol 2016. [DOI: 10.1016/j.cjca.2016.07.389] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
38
|
Bernatsky S, Ramsey-Goldman R, Petri M, Urowitz MB, Gladman DD, Fortin PR, Ginzler E, Romero-Diaz J, Peschken C, Jacobsen S, Hanly JG, Gordon C, Nived O, Yelin EH, Isenberg D, Rahman A, Bae SC, Joseph L, Witte T, Ruiz-Irastorza G, Aranow C, Kamen D, Sturfeldt G, Foulkes WD, Hansen JE, St Pierre Y, Raymer PC, Tessier-Cloutier B, Clarke AE. Breast cancer in systemic lupus. Lupus 2016; 26:311-315. [PMID: 27687028 DOI: 10.1177/0961203316664595] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Objective There is a decreased breast cancer risk in systemic lupus erythematosus (SLE) versus the general population. We assessed a large sample of SLE patients, evaluating demographic and clinical characteristics and breast cancer risk. Methods We performed case-cohort analyses within a multi-center international SLE sample. We calculated the breast cancer hazard ratio (HR) in female SLE patients, relative to demographics, reproductive history, family history of breast cancer, and time-dependent measures of anti-dsDNA positivity, cumulative disease activity, and drugs, adjusted for SLE duration. Results There were 86 SLE breast cancers and 4498 female SLE cancer-free controls. Patients were followed on average for 7.6 years. Versus controls, SLE breast cancer cases tended to be white and older. Breast cancer cases were similar to controls regarding anti-dsDNA positivity, disease activity, and most drug exposures over time. In univariate and multivariate models, the principal factor associated with breast cancers was older age at cohort entry. Conclusions There was little evidence that breast cancer risk in this SLE sample was strongly driven by any of the clinical factors that we studied. Further search for factors that determine the lower risk of breast cancer in SLE may be warranted.
Collapse
Affiliation(s)
- S Bernatsky
- 1 Faculty of Medicine, McGill University, Montreal, Canada.,2 Division of Clinical Epidemiology, Research Institute of the McGill University Health Center, Montreal, Canada
| | - R Ramsey-Goldman
- 3 Feinberg School of Medicine, Northwestern University, Chicago, USA
| | - M Petri
- 4 Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, USA
| | - M B Urowitz
- 5 Center for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, Canada
| | - D D Gladman
- 5 Center for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, Canada
| | - P R Fortin
- 6 Division of Rheumatology, Centre de recherche du CHU de Québec-Université Laval, Quebec City, Canada
| | - E Ginzler
- 7 State University of New York-Downstate Medical Center, New York, USA
| | - J Romero-Diaz
- 8 Instituto Nacional de Ciencias Medicas y Nutrición, Mexico City, Mexico
| | - C Peschken
- 9 University of Manitoba, Winnipeg, Canada
| | - S Jacobsen
- 10 Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
| | - J G Hanly
- 11 Division of Rheumatology, Dalhousie University and Nova Scotia Health Authority, Halifax, Canada
| | - C Gordon
- 12 Rheumatology Research Group, Institute for Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham: Rheumatology department, City Hospital, Sandwell and West Birmingham Hospitals NHS Trust and NIHR/Wellcome Trust Clinical Research Facility, Queen Elizabeth Hospital Birmingham; University Hospital Birmingham NHS Foundation Trust, Birmingham, UK
| | - O Nived
- 13 Department of Rheumatology, Institution of Clinical Sciences, Lund University Hospital, Lund, Sweden
| | - E H Yelin
- 14 Department of Medicine, University of California, San Francisco, USA
| | - D Isenberg
- 15 Centre for Rheumatology Research, University College London, London, UK
| | - A Rahman
- 15 Centre for Rheumatology Research, University College London, London, UK
| | - S-C Bae
- 16 The Hospital for Rheumatic Diseases, Hanyang University, Seoul, Korea
| | - L Joseph
- 1 Faculty of Medicine, McGill University, Montreal, Canada.,2 Division of Clinical Epidemiology, Research Institute of the McGill University Health Center, Montreal, Canada
| | - T Witte
- 17 Department of Clinical Immunology, Hannover Medical School, Hannover, Germany
| | - G Ruiz-Irastorza
- 18 Autoimmune Diseases Research Unit, Department Of Internal Medicine, Hospital Universitario Cruces, University Of The Basque Country, Bizkaia, Spain
| | - C Aranow
- 19 Feinstein Institute for Medical Research, New York, USA
| | - D Kamen
- 20 Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, USA
| | - G Sturfeldt
- 13 Department of Rheumatology, Institution of Clinical Sciences, Lund University Hospital, Lund, Sweden
| | - W D Foulkes
- 21 Departments of Oncology, Human Genetics and Medicine, McGill University, Montreal, Canada
| | - J E Hansen
- 22 Department of Therapeutic Radiology, Yale School of Medicine, New Haven, USA
| | - Y St Pierre
- 2 Division of Clinical Epidemiology, Research Institute of the McGill University Health Center, Montreal, Canada
| | - P Chrétien Raymer
- 2 Division of Clinical Epidemiology, Research Institute of the McGill University Health Center, Montreal, Canada
| | - B Tessier-Cloutier
- 23 Department of Anatomical Pathology, University of British Colombia, Vancouver, Canada
| | - A E Clarke
- 24 Division of Rheumatology, University of Calgary, Calgary, Canada
| |
Collapse
|
39
|
Joseph L, Cankovic M, Caughron S, Chandra P, Emmadi R, Hagenkord J, Hallam S, Jewell KE, Klein RD, Pratt VM, Rothberg PG, Temple-Smolkin RL, Lyon E. The Spectrum of Clinical Utilities in Molecular Pathology Testing Procedures for Inherited Conditions and Cancer: A Report of the Association for Molecular Pathology. J Mol Diagn 2016; 18:605-619. [PMID: 27542512 DOI: 10.1016/j.jmoldx.2016.05.007] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2015] [Revised: 05/18/2016] [Accepted: 05/26/2016] [Indexed: 12/24/2022] Open
Abstract
Clinical utility describes the benefits of each laboratory test for that patient. Many stakeholders have adopted narrow definitions for the clinical utility of molecular testing as applied to targeted pharmacotherapy in oncology, regardless of the population tested or the purpose of the testing. This definition does not address all of the important applications of molecular diagnostic testing. Definitions consistent with a patient-centered approach emphasize and recognize that a clinical test result's utility depends on the context in which it is used and are particularly relevant to molecular diagnostic testing because of the nature of the information they provide. Debates surrounding levels and types of evidence needed to properly evaluate the clinical value of molecular diagnostics are increasingly important because the growing body of knowledge, stemming from the increase of genomic medicine, provides many new opportunities for molecular testing to improve health care. We address the challenges in defining the clinical utility of molecular diagnostics for inherited diseases or cancer and provide assessment recommendations. Starting with a modified analytic validity, clinical validity, clinical utility, and ethical, legal, and social implications model for addressing clinical utility of molecular diagnostics with a variety of testing purposes, we recommend promotion of patient-centered definitions of clinical utility that appropriately recognize the valuable contribution of molecular diagnostic testing to improve patient care.
Collapse
Affiliation(s)
- Loren Joseph
- Association for Molecular Pathology's Framework for the Evidence Needed to Demonstrate Clinical Utility Task Force, Bethesda, Maryland; Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
| | - Milena Cankovic
- Association for Molecular Pathology's Framework for the Evidence Needed to Demonstrate Clinical Utility Task Force, Bethesda, Maryland; Department of Pathology and Laboratory Medicine, Henry Ford Hospital, Detroit, Michigan
| | - Samuel Caughron
- Association for Molecular Pathology's Framework for the Evidence Needed to Demonstrate Clinical Utility Task Force, Bethesda, Maryland; MAWD Pathology Group, PA, North Kansas City, Missouri
| | - Pranil Chandra
- Association for Molecular Pathology's Framework for the Evidence Needed to Demonstrate Clinical Utility Task Force, Bethesda, Maryland; PathGroup, LLC, Brentwood, Tennessee
| | - Rajyasree Emmadi
- Association for Molecular Pathology's Framework for the Evidence Needed to Demonstrate Clinical Utility Task Force, Bethesda, Maryland; Department of Pathology, College of Medicine, University of Illinois at Chicago, Chicago, Illinois
| | - Jill Hagenkord
- Association for Molecular Pathology's Framework for the Evidence Needed to Demonstrate Clinical Utility Task Force, Bethesda, Maryland; 23andMe, Inc., Mountain View, California
| | - Stephanie Hallam
- Association for Molecular Pathology's Framework for the Evidence Needed to Demonstrate Clinical Utility Task Force, Bethesda, Maryland; Good Start Genetics, Inc., Cambridge, Massachusetts
| | - Kay E Jewell
- Association for Molecular Pathology's Framework for the Evidence Needed to Demonstrate Clinical Utility Task Force, Bethesda, Maryland; Tara Center, LLC, Stevens Point, Wisconsin
| | - Roger D Klein
- Association for Molecular Pathology's Framework for the Evidence Needed to Demonstrate Clinical Utility Task Force, Bethesda, Maryland; Department of Molecular Pathology, Cleveland Clinic, Cleveland, Ohio
| | - Victoria M Pratt
- Association for Molecular Pathology's Framework for the Evidence Needed to Demonstrate Clinical Utility Task Force, Bethesda, Maryland; Department of Medical and Molecular Genetics, School of Medicine, Indiana University, Indianapolis, Indiana
| | - Paul G Rothberg
- Association for Molecular Pathology's Framework for the Evidence Needed to Demonstrate Clinical Utility Task Force, Bethesda, Maryland; Department of Pathology and Laboratory Medicine, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, New York
| | | | - Elaine Lyon
- Association for Molecular Pathology's Framework for the Evidence Needed to Demonstrate Clinical Utility Task Force, Bethesda, Maryland; Department of Pathology, University of Utah School of Medicine and ARUP Laboratories, Salt Lake City, Utah.
| |
Collapse
|
40
|
Mustafi R, Dougherty U, Mustafi D, Ayaloglu-Butun F, Fletcher M, Adhikari S, Sadiq F, Meckel K, Haider HI, Khalil A, Pekow J, Konda V, Joseph L, Hart J, Fichera A, Li YC, Bissonnette M. ADAM17 is a Tumor Promoter and Therapeutic Target in Western Diet-associated Colon Cancer. Clin Cancer Res 2016; 23:549-561. [PMID: 27489286 DOI: 10.1158/1078-0432.ccr-15-3140] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2016] [Revised: 07/18/2016] [Accepted: 07/25/2016] [Indexed: 12/30/2022]
Abstract
PURPOSE Epidermal growth factor receptors (EGFR) are required for tumor promotion by Western diet. The metalloprotease, ADAM17 activates EGFR by releasing pro-EGFR ligands. ADAM17 is regulated by G-protein-coupled receptors, including CXCR4. Here we investigated CXCR4-ADAM17 crosstalk and examined the role of ADAM17 in tumorigenesis. EXPERIMENTAL DESIGN We used CXCR4 inhibitor, AMD3100 and ADAM17 inhibitor, BMS566394 to assess CXCR4-ADAM17 crosstalk in colon cancer cells. We compared the expression of CXCR4 ligand, CXCL2, and ADAM17 in mice fed Western diet versus standard diet. Separately, mice were treated with marimastat, a broad-spectrum ADAM17 inhibitor, or AMD3100 to assess EGFR activation by ADAM17 and CXCR4. Using Apc-mutant Min mice, we investigated the effects of ADAM17/10 inhibitor INCB3619 on tumorigenesis. To assess the effects of colonocyte ADAM17, mice with ADAM17 conditional deletion were treated with azoxymethane (AOM). ADAM17 expression was also compared in colonocytes from primary human colon cancers and adjacent mucosa. RESULTS CXCL12 treatment activated colon cancer cell EGFR signals, and CXCR4 or ADAM17 blockade reduced this activation. In vivo, Western diet increased CXCL12 in stromal cells and TGFα in colonocytes. Marimastat or AMD3100 caused >50% reduction in EGFR signals (P < 0.05). In Min mice, INCB3619 reduced EGFR signals in adenomas and inhibited intestinal tumor multiplicity (P < 0.05). In the AOM model, colonocyte ADAM17 deletion reduced EGFR signals and colonic tumor development (P < 0.05). Finally, ADAM17 was upregulated >2.5-fold in human malignant colonocytes. CONCLUSIONS ADAM17 is a Western diet-inducible enzyme activated by CXCL12-CXCR4 signaling, suggesting the pathway: Western diet→CXCL12→CXCR4→ADAM17→TGFα→EGFR. ADAM17 might serve as a druggable target in chemoprevention strategies. Clin Cancer Res; 23(2); 549-61. ©2016 AACR.
Collapse
Affiliation(s)
- Reba Mustafi
- Department of Medicine, University of Chicago, Chicago IL 60637
| | | | - Devkumar Mustafi
- Department of Radiology, University of Chicago, Chicago IL 60637
| | | | | | | | - Farhana Sadiq
- Department of Medicine, University of Chicago, Chicago IL 60637
| | | | - Haider I Haider
- Department of Medicine, University of Chicago, Chicago IL 60637
| | | | - Joel Pekow
- Department of Medicine, University of Chicago, Chicago IL 60637
| | - Vani Konda
- Department of Medicine, University of Chicago, Chicago IL 60637
| | - Loren Joseph
- Department of Pathology, University of Chicago, Chicago IL 60637
| | - John Hart
- Department of Pathology, University of Chicago, Chicago IL 60637
| | | | - Yan Chun Li
- Department of Medicine, University of Chicago, Chicago IL 60637
| | | |
Collapse
|
41
|
Abstract
INTRODUCTION Next-Generation-Sequencing (NGS) has enabled gene mutation profiling - cataloguing sequence variants and modifications in clinical assays encompassing tens to thousands of genes in tumors and in germlines. The clinical benefit of applying multi-gene NGS to diverse applications in various malignancies remains to be demonstrated. AREAS COVERED Applications of gene mutation profiling in oncology include screening cancer-prone families, classification of malignancies, treatment selection, and monitoring the response to treatment of solid tumors (the 'liquid biopsy'). Google Scholar was used to search PubMed for the period 2011-2016 using combinations of the following search terms: 'clinical utility', NGS, 'molecular diagnostics'. Expert commentary: Clinical studies are in progress pairing mutation profiling with streamlined new trial designs to speed identification of promising drug-target combinations and to see if genotype-informed treatment selection will improve outcome across a spectrum of histologies. The analytical advantages and falling cost of NGS make focused gene panels likely to become the dominant modality in molecular diagnostic testing even if trials eventually discourage use of large panels to test all malignancies.
Collapse
Affiliation(s)
- Loren Joseph
- a Department of Pathology, Beth Israel Deaconess Medical Center, Molecular Diagnostics Laboratory , Harvard Medical School , Boston , MA , USA
| |
Collapse
|
42
|
Vignier N, Faure Grise D, Jeannerod V, Verdavaine G, Joseph L, Diamantis S, Binart M. MIG-02 - Pathologies infectieuses rencontrées dans une consultation d’accès aux soins et aux droits. Med Mal Infect 2016. [DOI: 10.1016/s0399-077x(16)30445-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
43
|
Aisner DL, Berry A, Dawson DB, Hayden RT, Joseph L, Hill CE. A Suggested Molecular Pathology Curriculum for Residents. J Mol Diagn 2016; 18:153-62. [DOI: 10.1016/j.jmoldx.2015.10.006] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2015] [Revised: 09/23/2015] [Accepted: 10/16/2015] [Indexed: 11/28/2022] Open
|
44
|
Joseph L, Jeanmonod R, Jeanmonod D. 294 A Comparison of Ultrasound-Guided and Palpation-Guided Identification of Lumbar Puncture Needle Entry Site in Patients as Body Mass Index Increases. Ann Emerg Med 2015. [DOI: 10.1016/j.annemergmed.2015.07.328] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
45
|
Joseph L, Paul H, Premkumar J, Paul R, Michael JS. Biomedical waste management: study on the awareness and practice among healthcare workers in a tertiary teaching hospital. Indian J Med Microbiol 2015; 33:129-31. [PMID: 25560016 DOI: 10.4103/0255-0857.148411] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Bio-medical waste has a higher potential of infection and injury to the healthcare worker, patient and the surrounding community. Awareness programmes on their proper handling and management to healthcare workers can prevent the spread of infectious diseases and epidemics. This study was conducted in a tertiary care hospital to assess the impact of training, audits and education/implementations from 2009 to 2012 on awareness and practice of biomedical waste segregation. Our study reveals focused training, strict supervision, daily surveillance, audits inspections, involvement of hospital administrators and regular appraisals are essential to optimise the segregation of biomedical waste.
Collapse
Affiliation(s)
| | | | | | | | | | - J S Michael
- Department of Clinical Microbiology , Christian Medical College and Hospital, Vellore, Tamil Nadu, India
| |
Collapse
|
46
|
Rangachari D, VanderLaan PA, Le X, Folch E, Kent MS, Gangadharan SP, Majid A, Haspel RL, Joseph L, Huberman M, Costa DB. A single center experience with next generation sequencing (NGS) for the care of advanced non-small-cell lung cancer (NSCLC). J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.e19109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Deepa Rangachari
- Beth Israel Deaconess Medcl Center/Harvard Medical School, Boston, MA
| | - Paul A VanderLaan
- Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA
| | - Xiuning Le
- Beth Israel Deaconess Medcl Ctr, Boston, MA
| | - Erik Folch
- Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA
| | - Michael S Kent
- Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
| | | | - Adnan Majid
- Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA
| | - Richard L. Haspel
- Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA
| | - Loren Joseph
- Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA
| | - Mark Huberman
- Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA
| | | |
Collapse
|
47
|
Lane N, Lahham S, Joseph L, Bahner DP, Fox JC. Ultrasound in medical education: listening to the echoes of the past to shape a vision for the future. Eur J Trauma Emerg Surg 2015; 41:461-7. [PMID: 26038053 DOI: 10.1007/s00068-015-0535-7] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2015] [Accepted: 04/18/2015] [Indexed: 01/16/2023]
Abstract
PURPOSE Ultrasound in medical education has seen a tremendous growth over the last 10-20 years but ultrasound technology has been around for hundreds of years and sound has an even longer scientific history. The development of using sound and ultrasound to understand our body and our surroundings has been a rich part of human history. From the development of materials to produce piezoelectric conductors, ultrasound has been used and improved in many industries and medical specialties. METHODS As diagnostic medical ultrasound has improved its resolution and become more portable, various specialties from radiology, cardiology, obstetrics and more recently emergency, critical care and proceduralists have found the added benefits of using ultrasound to safely help patients. The past advancements in technology have established the scaffold for the possibilities of diagnostic ultrasound's use in the present and future. RESULTS A few medical educators have integrated ultrasound into medical school while a wealth of content exists online for learning ultrasound. Twenty-first century learners prefer blended learning where material can be reviewed online and personalize the education on their own time frame. This material combined with hands-on experience and mentorship can be used to develop learners' aptitude in ultrasound. CONCLUSIONS As educators embrace this ultrasound technology and integrate it throughout the medical education journey, collaboration across specialties will synthesize a clear path forward when needs and resources are paired with vision and a strategic plan.
Collapse
Affiliation(s)
- N Lane
- Irvine School of Medicine, University of California, Irvine, USA
| | - S Lahham
- Irvine School of Medicine, University of California, Irvine, USA
| | - L Joseph
- Irvine School of Medicine, University of California, Irvine, USA
| | - D P Bahner
- The Ohio State University, 756 Prior Hall, 376 W. 10th Avenue, Columbus, OH, 43210, USA.
| | - J C Fox
- Irvine School of Medicine, University of California, Irvine, USA.
| |
Collapse
|
48
|
Li Z, Stölzel F, Onel K, Sukhanova M, Mirza MK, Yap KL, Borinets O, Larson RA, Stock W, Sasaki MM, Joseph L, Raca G. Next-generation sequencing reveals clinically actionable molecular markers in myeloid sarcoma. Leukemia 2015; 29:2113-6. [PMID: 25787914 PMCID: PMC4575593 DOI: 10.1038/leu.2015.81] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Affiliation(s)
- Z Li
- Department of Human Genetics, The University of Chicago Medical Center, Chicago, IL, USA
| | - F Stölzel
- Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus Dresden, Technical University Dresden, Dresden, Germany
| | - K Onel
- Department of Pediatrics, The University of Chicago Medical Center, Chicago, IL, USA
| | - M Sukhanova
- Department of Medicine, The University of Chicago Medical Center, Chicago, IL, USA
| | - M K Mirza
- Department of Pathology, The University of Chicago Medical Center, Chicago, IL, USA
| | - K L Yap
- Department of Medicine, The University of Chicago Medical Center, Chicago, IL, USA
| | - O Borinets
- Department of Medicine, The University of Chicago Medical Center, Chicago, IL, USA
| | - R A Larson
- Department of Medicine, The University of Chicago Medical Center, Chicago, IL, USA
| | - W Stock
- Department of Medicine, The University of Chicago Medical Center, Chicago, IL, USA
| | - M M Sasaki
- Department of Pediatrics, The University of Chicago Medical Center, Chicago, IL, USA
| | - L Joseph
- Department of Pathology, The University of Chicago Medical Center, Chicago, IL, USA
| | - G Raca
- Department of Medicine, The University of Chicago Medical Center, Chicago, IL, USA
| |
Collapse
|
49
|
Hegde M, Bale S, Bayrak-Toydemir P, Gibson J, Jeng LJB, Joseph L, Laser J, Lubin IM, Miller CE, Ross LF, Rothberg PG, Tanner AK, Vitazka P, Mao R. Reporting incidental findings in genomic scale clinical sequencing--a clinical laboratory perspective: a report of the Association for Molecular Pathology. J Mol Diagn 2015; 17:107-17. [PMID: 25684271 DOI: 10.1016/j.jmoldx.2014.10.004] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2014] [Revised: 09/27/2014] [Accepted: 10/21/2014] [Indexed: 12/17/2022] Open
Abstract
Advances in sequencing technologies have facilitated concurrent testing for many disorders, and the results generated may provide information about a patient's health that is unrelated to the clinical indication, commonly referred to as incidental findings. This is a paradigm shift from traditional genetic testing in which testing and reporting are tailored to a patient's specific clinical condition. Clinical laboratories and physicians are wrestling with this increased complexity in genomic testing and reporting of the incidental findings to patients. An enormous amount of discussion has taken place since the release of a set of recommendations from the American College of Medical Genetics and Genomics. This discussion has largely focused on the content of the incidental findings, but the laboratory perspective and patient autonomy have been overlooked. This report by the Association of Molecular Pathology workgroup discusses the pros and cons of next-generation sequencing technology, potential benefits, and harms for reporting of incidental findings, including the effect on both the laboratory and the patient, and compares those with other areas of medicine. The importance of genetic counseling to preserve patient autonomy is also reviewed. The discussion and recommendations presented by the workgroup underline the need for continued research and discussion among all stakeholders to improve our understanding of the effect of different policies on patients, providers, and laboratories.
Collapse
Affiliation(s)
- Madhuri Hegde
- Incidental Findings Working Group of the Association for Molecular Pathology (AMP) Clinical Practice Committee and the Whole Genome Analysis Working Group, Bethesda, Maryland; Department of Human Genetics, Emory University School of Medicine, Atlanta, Georgia; Emory Genetics Laboratory, Emory University, Decatur, Georgia.
| | - Sherri Bale
- Incidental Findings Working Group of the Association for Molecular Pathology (AMP) Clinical Practice Committee and the Whole Genome Analysis Working Group, Bethesda, Maryland; GeneDx, Gaithersburg, Maryland
| | - Pinar Bayrak-Toydemir
- Incidental Findings Working Group of the Association for Molecular Pathology (AMP) Clinical Practice Committee and the Whole Genome Analysis Working Group, Bethesda, Maryland; Department of Pathology, University of Utah School of Medicine, Salt Lake City, Utah; Department of Molecular Genetics, ARUP Laboratories, Salt Lake City, Utah
| | - Jane Gibson
- Incidental Findings Working Group of the Association for Molecular Pathology (AMP) Clinical Practice Committee and the Whole Genome Analysis Working Group, Bethesda, Maryland; Department of Clinical Sciences, University of Central Florida College of Medicine, Orlando, Florida
| | - Linda Jo Bone Jeng
- Incidental Findings Working Group of the Association for Molecular Pathology (AMP) Clinical Practice Committee and the Whole Genome Analysis Working Group, Bethesda, Maryland; Division of Endocrinology, Diabetes and Nutrition, Department of Medicine, Department of Pathology, and Division of Human Genetics, Department of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland
| | - Loren Joseph
- Incidental Findings Working Group of the Association for Molecular Pathology (AMP) Clinical Practice Committee and the Whole Genome Analysis Working Group, Bethesda, Maryland; Department of Pathology, University of Chicago, Chicago, Illinois
| | - Jordan Laser
- Incidental Findings Working Group of the Association for Molecular Pathology (AMP) Clinical Practice Committee and the Whole Genome Analysis Working Group, Bethesda, Maryland; Division of Cytogenetics and Molecular Pathology, North Shore Long Island Jewish Health System, New Hyde Park, New York
| | - Ira M Lubin
- Incidental Findings Working Group of the Association for Molecular Pathology (AMP) Clinical Practice Committee and the Whole Genome Analysis Working Group, Bethesda, Maryland; Division of Laboratory Programs, Standards, and Services, Centers for Disease Control and Prevention, Atlanta, Georgia
| | - Christine E Miller
- Incidental Findings Working Group of the Association for Molecular Pathology (AMP) Clinical Practice Committee and the Whole Genome Analysis Working Group, Bethesda, Maryland; Department of Molecular Genetics, ARUP Laboratories, Salt Lake City, Utah
| | - Lainie F Ross
- Incidental Findings Working Group of the Association for Molecular Pathology (AMP) Clinical Practice Committee and the Whole Genome Analysis Working Group, Bethesda, Maryland; Department of Pediatrics, University of Chicago, Chicago, Illinois; MacLean Center for Clinical Medical Ethics, University of Chicago, Chicago, Illinois
| | - Paul G Rothberg
- Incidental Findings Working Group of the Association for Molecular Pathology (AMP) Clinical Practice Committee and the Whole Genome Analysis Working Group, Bethesda, Maryland; Department of Pathology and Laboratory Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York
| | - Alice K Tanner
- Incidental Findings Working Group of the Association for Molecular Pathology (AMP) Clinical Practice Committee and the Whole Genome Analysis Working Group, Bethesda, Maryland; Department of Human Genetics, Emory University School of Medicine, Atlanta, Georgia; Emory Genetics Laboratory, Emory University, Decatur, Georgia
| | - Patrik Vitazka
- Incidental Findings Working Group of the Association for Molecular Pathology (AMP) Clinical Practice Committee and the Whole Genome Analysis Working Group, Bethesda, Maryland; GeneDx, Gaithersburg, Maryland
| | - Rong Mao
- Incidental Findings Working Group of the Association for Molecular Pathology (AMP) Clinical Practice Committee and the Whole Genome Analysis Working Group, Bethesda, Maryland; Department of Pathology, University of Utah School of Medicine, Salt Lake City, Utah; Department of Molecular Genetics, ARUP Laboratories, Salt Lake City, Utah
| |
Collapse
|
50
|
Pekow J, Meckel K, Dougherty U, Butun F, Mustafi R, Lim J, Crofton C, Chen X, Joseph L, Bissonnette M. Tumor suppressors miR-143 and miR-145 and predicted target proteins API5, ERK5, K-RAS, and IRS-1 are differentially expressed in proximal and distal colon. Am J Physiol Gastrointest Liver Physiol 2015; 308:G179-87. [PMID: 25477374 PMCID: PMC4312953 DOI: 10.1152/ajpgi.00208.2014] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
The colon differs regionally in local luminal environment, excretory function, and gene expression. Polycistronic microRNA (miR)-143 and miR-145 are downregulated early in colon cancer. We asked if these microRNAs (miRNAs) might be differentially expressed in the proximal vs. the distal colon, contributing to regional differences in protein expression. Primary transcripts and mature miR-143 and miR-145 were quantified by real-time PCR, putative targets were measured by Western blotting, and DNA methylation was assessed by sequencing bisulfite-treated DNA in proximal and distal normal colonic mucosa as well as colon cancers. Putative targets of these miRNAs were assessed following transfection with miR-143 or miR-145. Mean expression of mature miR-143 and miR-145 was 2.0-fold (P < 0.001) and 1.8-fold (P = 0.03) higher, respectively, in proximal than distal colon. DNA methylation or primary transcript expression of these miRNAs did not differ by location. In agreement with increased expression of miR-143 and miR-145 in proximal colon, predicted targets of these miRNAs, apoptosis inhibitor 5 (API5), ERK5, K-RAS, and insulin receptor substrate 1 (IRS-1), which are cell cycle and survival regulators, were expressed at a lower level in proximal than distal colon. Transfection of HCA-7 colon cancer cells with miR-145 downregulated IRS-1, and transfection of HT-29 colon cancer cells with miR-143 decreased K-RAS and ERK5 expression. In conclusion, miR-143 and miR-145 and the predicted target proteins API5, ERK5, K-RAS, and IRS-1 display regional differences in expression in the colon. We speculate that differences in these tumor suppressors might contribute to regional differences in normal colonic gene expression and modulate site-specific differences in malignant predisposition.
Collapse
Affiliation(s)
- Joel Pekow
- Section of Gastroenterology, Hepatology, and Nutrition, University of Chicago, Chicago, Illinois; and
| | - Katherine Meckel
- 1Section of Gastroenterology, Hepatology, and Nutrition, University of Chicago, Chicago, Illinois; and
| | - Urszula Dougherty
- 1Section of Gastroenterology, Hepatology, and Nutrition, University of Chicago, Chicago, Illinois; and
| | - Fatma Butun
- 1Section of Gastroenterology, Hepatology, and Nutrition, University of Chicago, Chicago, Illinois; and
| | - Reba Mustafi
- 1Section of Gastroenterology, Hepatology, and Nutrition, University of Chicago, Chicago, Illinois; and
| | - John Lim
- 1Section of Gastroenterology, Hepatology, and Nutrition, University of Chicago, Chicago, Illinois; and
| | - Charis Crofton
- 1Section of Gastroenterology, Hepatology, and Nutrition, University of Chicago, Chicago, Illinois; and
| | - Xindi Chen
- 1Section of Gastroenterology, Hepatology, and Nutrition, University of Chicago, Chicago, Illinois; and
| | - Loren Joseph
- 2Department of Pathology, University of Chicago, Chicago, Illinois
| | - Marc Bissonnette
- 1Section of Gastroenterology, Hepatology, and Nutrition, University of Chicago, Chicago, Illinois; and
| |
Collapse
|